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Der Coxsackievirus- und Adenovirusrezeptor (CAR) ist ein Typ I Transmembran-
protein, das an der Adsorption von Viren und der Aufrechterhaltung von Zell-
Zellkontakten beteiligt ist. Er wird hauptsächlich im sich entwickelnden Gehirn 
und Herzen exprimiert, sowie bei Herzkerkrankungen, die zu strukturellen 
Veränderungen führen. Coxsackievirus B3 (CVB3) Infektionen sind eine häufige 
Ursache für akute Myokarditis, die bei Patienten häufig zu chronischer 
Kardiomyopathie mit Fibrose und reduzierter Kontraktilität des Herzens bis zur 
Herzinsuffizienz führen können. CAR ist für die Aufnahme von Viren in 
unterschiedliche Zelltypen verantwortlich und damit ein potentielles Ziel bei der 
Therapie und Prävention von CVB3-Infektionen. Um die Rolle von CAR in der 
Pathogenese von inflammatorischen Herzerkrankungen zu verstehen, wurde eine 
konditionelle Knockout-Strategie verwendent. Der resultierende herzspezifisch 
induzierbare und komplette Knockout des Gens erlaubt die Untersuchung von 
CAR in der Embryonalentwicklung und im erwachsenen Herzen. 
Der komplette Knockout von CAR ist embryonal letal (E11.5). Die betroffenen 
Embryonen zeigten Missbildungen des Herzens mit verstärker Einlagerung von 
Apoliproteinen. Dies deutet auf eine Rolle von CAR in der Aufnahme von 
Lipiden. Weiterhin konnte eine reduzierte Expression von Connexinen im 
Knockout beobachtet werden – ein mögliches Zeichen gestörter interzellulärer 
Kommunikation. 
Mit Hilfe des MerCreMer Transgens konnten wir Tiere züchten, die nach 
Induktion mit Tamoxifen eine reduzierte Expression von CAR im Herzen 
aufwiesen. In diesen Tieren führte die Infektion mit CVB3 im Gegensatz zu 
CVB3-infizierten Wildtyp Kontrolltieren zu keinen pathologischen 
Veränderungen wie z.B. Infiltration mit Mononukleären Zellen und Fibrose oder 




Kontrolltieren − die kontraktile Funktion des CVB3-infizierten Knockout Herzen 
erhalten.  
Um mögliche unerwünschte Konsequenzen aus dem Verlust von CAR zu 
untersuchen, wurde eine umfassende kardiale Phänotypisierung durchgeführt, die 
eine elektrische Reizleitunsstörung (AV-block) im Knockout-Herzen zeigte. Der 
zugrunde liegende Mechanismus betrifft die Interaktion von Tight- und Gap-
Junctions mit veränderter Expression und Lokalisierung von Connexinen, sowie 
die interzelluläre Kommunikation zwischen CAR-Knockout Kardiomyzeten. 
CAR ist essentiell für eine normale Embryonalentwicklung und kardiale Funktion. 
Das CAR-Knockout-Modell bietet einerseits den ersten genetischen Hinweis für 
eine Rolle von CAR als Virusrezeptor in vivo und belegt andererseits die Relevanz 
von direkter Virus-vermittelter Symptomatik gegenüber einer sekundären 
autoimmun- Komponente in CVB3-induzierten Herzerkrankungen. Damit ist 
CAR ein potentielles therapeutisches Target in der Prävention und Behandlung 
von viraler Myokarditis.  
 
Schlagwörter: 
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The coxsackievirus and adenovirus receptor (CAR) is a type I transmembrane 
protein involved in virus uptake and the maintenance of cell-cell contacts. It is 
predominantly expressed in the developing brain and heart, and re-induced upon 
cardiac remodeling in heart disease. 
Coxsackievirus B3 (CVB3) infections are frequent causes of human acute myo-
carditis, often resulting in chronic cardiomyopathy with fibrosis and reduced con-
tractile function that may progress into terminal heart failure. The coxsackievirus 
and adenovirus receptor (CAR) is involved in virus uptake into various cell types 
and has therefore been suggested as a therapeutic target to prevent or treat CVB3 
induced diseases such as myocarditis and cardiomyopathy. To understand the role 
of CAR in the pathogenesis of inflammatory heart disease we used conditional 
knockout approach. The inducible heart-specific and the complete knockout mod-
el enabled us to study CAR’s role in embryonic development and in the adult an-
imal heart. 
The complete CAR-knockout was embryonic lethal at midgestation (E11.5) with 
cardiac malformation such as ventricular hypertrophy and atrial dilation. Apolipo-
proteins were accumulated in the knockout heart, indicating a role for CAR in 
lipid uptake. Connexin expression was decreased in the knockout, suggesting an 
abnormal cell-cell communication secondary to the loss of CAR. 
Using the MerCreMer transgene we were able to obtain adult animals that can be 
induced with tamoxifen to progressively lose CAR expression in the heart. The 
role of CAR in murine viral myocarditis was investigated using the inducible 
CAR-knockout infected with CVB3. Unlike control animals exposed to CVB3, 
the cardiac inducible knockout mice did not exhibit structural changes such as 
monocyte infiltration and fibrosis following CVB3 infection, or increased produc-





tractile dysfunction in the hearts of animals that express wildtype CAR, the CAR 
deficient hearts were essentially normal. 
To evaluate possible adverse effects that might result from CAR deficiency, we 
implemented a detailed cardiac phenotyping protocol and found that CAR defi-
cient animals developed a conduction defect (AV nodal block). The underlying 
mechanism relates to the crosstalk of tight and gap junctions with altered expres-
sion and localization of connexins that affect the communication between CAR 
knockout cardiomyocytes. 
Thus, CAR is essential for embryonic development and normal cardiac function. 
The CAR-knockout does not only provide the first genetic evidence to establish 
CAR as the CVB3 receptor in vivo, but furthermore demonstrates the relevance of 
direct virus-mediated pathology versus a secondary autoimmune component in 
CVB3 induced heart disease. Our data suggest that CAR is a suitable target to 
help prevent and treat viral myocarditis. 
Keywords:  
Knockout, cardiac development, myocarditis, viruses, cell adhesion molecules, 






The initiation of virus entry is triggered by the attachment of viruses to receptors on the 
cell surface. Expression of specific receptors can be an important determinant of a cell’s 
susceptibility to infection and of virus tropism for particular tissues. The long sought cox-
sackievirus and adenovirus receptor (CAR), was first identified as a coxsackievirus B 
(CVB) receptor and later found to mediate uptake adenoviruses by binding fiber knob 
proteins (Carson et al., 1997; Tomko et al., 1997; Bergelson et al., 1997). Due to wide-
spread interest in utilizing adenoviruses as vectors for therapeutic gene delivery, consi-
derable attention has been paid to the roles of CAR in virus tropism, and to its structural 
features important for virus attachment. CAR belongs to a growing subfamily of immu-
noglobulin-like surface molecules, many of which have been localized to sites of cell-cell 
contacts and appear to function in cell adhesion or intercellular recognition. CAR me-
diates homotypic cell-cell interactions and functions as a transmembrane component of 
the epithelial cell tight junction (Cohen et al., 2001b).  
1.1 The Coxsackievirus and Adenovirus Receptor (CAR) 
The coxsackievirus and adenovirus receptor (CAR) cDNA was cloned independently by 
two groups using different techniques (Tomko et al., 1997; Bergelson et al., 1997) and the 
CAR protein was isolated and partially sequenced by another group concurrently in the 
year 1997 (Carson et al., 1997). CAR is a highly conserved type I transmembrane protein 
of the tight junction. The extracellular Ig-domains can mediate homotypic cell adhesion 
and uptake of adenovirus and coxsackievirus B (CVB). The cytoplasmic tail is alterna-
tively spliced and interacts with various adaptor proteins that link to signal transduction 
and endocytosis (Cohen et al., 2001b; Chung et al., 2005; Sollerbrant et al., 2003; Coyne 




CAR is ubiquitously expressed, predominantly in the developing brain and heart (Tomko 
et al., 1997). It has been found that CAR is re-induced upon cardiac remodeling such as in 
experimental autoimmune myocarditis (Ito et al., 2000), in human dilated cardiomyopathy 
(Noutsias et al., 2001), and in myocardial infarction (MI) in the rat (Fechner et al., 2003). 
CAR deficiency results in mid-embryonic lethality with pericardial edema. The underly-
ing molecular changes relate to CAR’s role in cell-cell contact formation with altered 
organization of the myofibrils as well as increased proliferation of cardiomyocytes (Dorn-
er et al., 2005; Chen et al., 2006). The weak expression of CAR on cardiomyocytes of the 
adult and healthy heart in contrast to the strong expression of CAR in cardiomyocytes of 
the developing and diseased heart may suggest a role of CAR during the formation of a 
functional myocardium and cardiac remodeling. 
1.1.1 CAR gene and splice isoforms 
The gene encoding human CAR is located on chromosome 21q11.2 and composed of 
seven exons and the transcription unit is around 57kb (Bowles et al., 1999). The murine 
CAR gene is located on mouse chromosome 16 (human chromosome 21) and at least 
eight exons have been identified (Chen et al., 2003). The mouse transcript contains an 
additional splice site 27kb downstream of exon 7. The transcription initiation site and the 
promoter elements have been mapped at approximately 150bp before the ATG translation 
start site. A number of mRNAs corresponding to alternative splice variants have been 
characterized and the longer form is predominant (Bergelson et al., 1998; Dorner et al., 
2004; Thoelen et al., 2001b). Several of these would encode transmembrane proteins with 
an intact extracellular domain, but with modifications of the cytoplasmic domain. RNA 
encoding CAR2 has been found in a number of tissues (Fechner et al., 2003; Bergelson et 
al., 1998), but expression of CAR3 appears to be restricted to the murine heart. In addi-




brane domain. Two longer forms, called CAR4/7 and CAR3/7) contain an intact D1 do-
main. A soluble form of CAR (CAR2/7) has been detected in human pleural fluid and in 
mouse serum, and has been shown to interfere with adenoviurs-mediated gene delivery 
(Bernal et al., 2002) and coxsackievirus infection (Dorner et al., 2004), and CAR express-
ing vesicles are shed into the medium of cultured cells (Carson, 2004). It is not clear 
which of them are produced in vivo, and their individual functions are poorly understood. 
It is not known whether this soluble CAR results from alternative splicing or from proteo-
lysis. 
 
Figure 1: CAR structure and splicing variants. CAR1 and CAR2 contain a cytoplasmic domain. CAR4/7 
and CAR3/7 contain only the D1 domain, CAR 2/7 has an incomplete D1 domain. SP: signal peptide, TM: 
transmembrane domain, D1: Ig-like domain 1, D2: Ig-like domain 2. 
1.1.2 CAR protein domain structure and function 
CAR cDNA encodes a 365 amino acid protein; cleavage of a 19-residue signal peptide 
results in a mature protein of 346 amino acids. CAR contains a single 23 amino acids 
membrane-spanning domain that separates an extracellular domain of 216 residues from a 
107 or 94 residue intercellular domain dependent on alternative splicing (Fig. 1). Those 
two splice isoforms are referred to as mCAR1 and mCAR2 for the mouse and hCAR1 
and hCAR2 for the human. The extracellular domain is composed of two immunoglobu-




domain, but the two viruses recognize different specific sites within D1 (Fig. 2) (He et al., 
2001; Bewley et al., 1999). Two membrane-proximal cytoplasmic cysteines are subject to 
fatty acid acylation (van't Hof and Crystal, 2002). The cytoplasmic part also contains po-
tential sites for phosphorylation and furin cleavage, and an extreme C-terminal hydro-
phobic peptide motif that interacts with PDZ-domain proteins (Xie et al., 2001). The pre-
dicted molecular weight of CAR is approximately 38kDa, but it migrates at 46kDa on 
SDS polyacrylamide gels, due to two N-linked glycans (Asn 106 and Asn 201). 
The predicted CAR structural model is supported and confirmed in biochemical and 
structural studies. The crystal structure of CAR D1 shows a β-sandwich fold characteris-
tic of Ig variable domains (Bewley et al., 1999; van Raaij et al., 2000; Jiang et al., 2004). 
The structural analysis of CAR D1 supports the proposed function which CAR mediates 
homotypic cell adhesion (Cohen et al., 2001b; Honda et al., 2000; Okegawa et al., 2001). 
It is speculated that D1 homodimerization explains CAR’s adhesive function. Within the 
crystal, D1 forms a homodimer; residues involved in dimerization are highly conserved in 
evolution, suggesting that the potential to dimerize is conserved and may be functionally 
important. D1 homodimers also form in solution; the measured dissociation constant of 
16 µM (van Raaij et al., 2000) is consistent with those measured for other cell adhesion 
molecules (Atkins et al., 1999; van der Merwe and Barclay, 1994; van der Merwe et al., 
1994). Furthermore, the dimerization is pH sensitive and ion pairing plays an important 
role in CAR D1 homodimer stabilization. However, there is no direct evidence that the 
dimers observed in the crystal are identical to those seen in solution, and it is not clear 
whether D1 dimerization is the mechanism of cell adhesion, or whether it represents an 
interaction that occurs between molecules side-by-side on a single cell surface. The crys-
tal structures of murine (Kostrewa et al., 2001) and human junctional adhesion molecule 
(JAM) (Prota et al., 2003), another tight junction protein, reveal a D1 dimer interface sim-




formed by pairs of molecules on the surface of a single cell, or whether it occurs between 
JAM molecules engaged across the intercellular junction. 
CAR D2 does not exhibit a high degree of sequence identity to other immunoglobulin 
domains, although it is also a member of the Ig superfamily. CAR D2 is shown to be a β-
sandwich motif comprised of two β-sheets, which are stabilized by two disulfide bonds 
by NMR spectroscopy. A lone helix encompassing residues 185-192 (referred as helix D) 
is found in the position of β-strand D of the c-type immunoglobulin fold. The surface of 
helix D is relatively hydrophobic, and offers a potential interaction site for the cellular 
partners of CAR (Jiang and Caffrey, 2007). 
Adenovirus interaction with CAR is mediated by fiber knob, an elongated fiber protein 
projecting from the virus capsid (Fig. 2C). adenovirus fiber binds to CAR with high affin-
ity (1nM) (Wickham et al., 1993) at a site similar to that involved in dimerization (Bew-
ley et al., 1999; van Raaij et al., 2000); fiber interaction with CAR might thus disrupt the 
low-affinity D1-D1 association. In fact, adenovirus fiber has been shown to dissociate 
CAR-mediated epithelial cell junctions (Walters et al., 2002), although the mechanism is 
not certain. The adenovirus fiber knob is a trimer, with globular knob domains arranged in 
a trefoil at its tip. The crystal structure of CAR D1 in association with the fiber knob re-
veals that three D1 domains bind to the outside of the knob (Bewley et al., 1999). In con-
trast, CVB attachment to CAR involves insertion of the D1 domain into a canyon on the 
virus surface, formed by VP1, VP2 and VP3 (He et al., 2001). VP1 dominates the interac-
tion with CAR D1. Thus whereas the D1 residues involved in Adenovirus interaction are 
clustered on one face of the domain, residues in contact with coxsackievirus are more 
widely distributed. The residues critical for CAR D1 homodimerization and for interac-
tions with Adenovirus and CVB3 are shown in figure 2. The surfaces of CAR D1 bind to 
CVB3, fiber knob, and CAR D1 itself are partially overlapped, possibly accounting for 




brane. Full-length CAR protein has higher affinity and stability than CAR D1 or CAR 
D1+D2 extracellular fragments, regarding to the binding to CVB3 (He et al., 2001). The 
cryoEM reconstruction of full-length CAR-CVB3 complexes shows that adjacent CAR 
molecules, which related by icosahedral two-fold axes, share common density in the ex-
ternal transmembrane and cytoplasmic regions. This bivalent association of the adjacent 
receptors might stabilize the complex with CVB3 or increase the possibility of forming 
saturated complexes. 
 
Figure 2: A) Stereo view of full length CAR bound to CVB3. The virus is represented as a grayscale sur-
face. Domains D1 and D2 of CAR are colored red, and the transmembrane and cytoplasmic regions are 
green. B) Stereo diagrams of the CAR D1 domain. The β-strands are labeled A–G. The amino acids identi-
fied as being in the virus–receptor interface are indicated by spheres. CAR with adenovirus knob in blue 
and CAR with CVB3 in red. C) Schematic diagram of the modes by which CAR (green) binds to CVB3 
(red) and adenovirus19 (blue). The suggested membrane curvature is speculative. CVB3: coxsackievirus 
B3, Ad: adenovirus. Figure adapted from (He et al., 2001). 
The cytoplasmic tail of CAR seems to be unnecessary for either CVB or adenovirus in-
fection (Wang and Bergelson, 1999), but it may be important for functions in cell signal-
ing, growth and correct subcellular localization. Apparently, the CAR cytoplasmic do-
main has a role in tumor cell growth, but the nature of the effect varies among reports 
using different cell types (Okegawa et al., 2001; Bruning et al., 2005). Binding of Adeno-
virus fiber knob to CAR on respiratory cells stimulates production of inflammatory prod-
ucts (Tamanini et al., 2006). Since inflammation is a key component of CVB-associated 




diseases. In addition to signaling, the cytoplasmic domain also influences CAR distribu-
tion within the cell (Cohen et al., 2001a; van't Hof and Crystal, 2002), and the carboxyl-
terminal PDZ-binding motif(s) association with PDZ-domain proteins has been estab-
lished. The absence of the intercellular tail results in the loss of targeting of CAR to tight 
junctions in vivo (Raschperger et al., 2006). 
The glycosylation of CAR does not alter cell surface levels or junctional localization, it 
affects both adhesion and adenovirus infection in unique ways. CAR-mediated adhesion 
appears to require at least one site of glycosylation. Glycosylation of the D2 domain is 
required for adenovirus cooperative binding, it has a negative consequence upon infection 
(Excoffon et al., 2007). 
1.1.3 Evolutionary conservation 
CAR has been identified in a variety of mammalian species (Noutsias et al., 2001; Tomko 
et al., 1997; Bergelson et al., 1998; Thoelen et al., 2001a), as well as in non-mammalian 
vertebrates such as fish and frog (Petrella et al., 2002), but no obvious CAR homologues 
could be found in Drosophila or nematodes. The overall homology between human, 
mouse, rat, dog, and pig CAR is about 90%. The D1 domain is more conserved (over 
90%) than the D2 domain, whereas the cytoplasmic tail is about 95% identical among 
these species. The transmembrane domain is less conserved and 77% identical between 
human and mouse. Zebrafish and human CAR are 44% identical over all. More extensive 
conservation within the cytoplasmic domain (66% identity) may suggest that this portion 
of the molecule participates in intercellular interactions that are also conserved. 
CAR belongs to a subfamily of proteins of which the original member is CTX, a putative 
receptor expressed on the surface of frog thymocytes (Chretien et al., 1996; Chretien et 
al., 1998). Proteins of the CTX family consist of two homolog extracellular Ig-loops of 




main, a transmembrane region, and a cytoplasmic tail of variable length. A subfamily of 
the CTX proteins also shows sequence conservation within the cytoplasmic domain. In 
particular, a 21-residue C-terminal peptide is extensively conserved. It is suspected that 
this peptide motif is responsible for interaction with some unidentified intracellular li-
gands (Coyne and Bergelson, 2005). 
Many of the CTX family members have been found to promote cell adhesion, and a num-
ber of family members have been localized to tight junctions. The best characterized 
among them is JAM. Four JAM isoforms mediate cell adhesion and localize to the tight 
junction, and JAM specific antibodies inhibit tight junction formation (Hirabayashi et al., 
2003; Cunningham et al., 2000; Aurrand-Lions et al., 2001; Liu et al., 2000). ESAM, an 
endothelial cell specific adhesion molecule, is expressed at endothelial cell junctions and 
appears to function in the vascular proliferation required for tumor growth (Hirata et al., 
2001; Ishida et al., 2003). The CAR like membrane protein CLMP, promotes homotypic 
cell adhesion and is expressed at the epithelial tight junction like JAM and CAR (Rasch-
perger et al., 2004). Other CTX family members include A33, an antigen expressed in 
colon carcinomas (Welt et al., 2003), a brain and testis specific Ig family member BT-IgS 
(Suzu et al., 2002), and a less well characterized Ig superfamily member 11 (IgSF11) ex-
pressed on intestinal cancer cells (Katoh and Katoh, 2003). Of these proteins, only CAR 
and JAM-A, a receptor for reovirus, have so far been identified as virus receptors. 
1.1.4 CAR expression  
1.1.4.1 CAR expression pattern in various tissues 
CAR is abundantly expressed in the mouse embryo with a preference for the nervous sys-
tem, including all neuroepithelial cells, in ganglions, and peripheral nerves (Tomko et al., 




the highest mRNA level is detected near birth and diminishing thereafter, though the tim-
ing of peak expression varied between regions of the brain (Honda et al., 2000). 
Detailed analysis of CAR protein expression has been facilitated by CAR specific antibo-
dies used in immunohistochemistry. A systematic survey of mouse tissues has been re-
ported (Raschperger et al., 2006). CAR can be detected in epithelial cells of embryonic 
liver, lung, heart, eye, pancreas, kidney, and the submandibular glands. In digestive and 
respiratory system, CAR specifically co-localizes with the tight junction protein ZO-1 and 
occludin. CAR has also been detected in trachea and bronchi but is absent from alveoli of 
adult animals. CAR is not detectable in connective tissue, smooth muscle cells, or endo-
thelial cells of the vasculature, including brain capillaries. In the adult rat, CAR protein is 
reportedly expressed primarily on epithelial derived cells in the liver, intestines, and lung 
(Tomko et al., 2000). 
In cultures of polarized epithelial cells, CAR is preferentially expressed at the basolateral 
side of the tight junctions, where it may be sequestered and inaccessible to virus, especial-
ly from the apical side (Cohen et al., 2001b; Walters et al., 2001). Although CAR may 
function as a homophilic cell adhesion molecule, it should be noted that CAR also has 
been detected on membrane regions other than tight junctions, for example on the luminal 
(apical) surface of the prostate epithelium (Bao et al., 2005; Rauen et al., 2002). In addi-
tion, CAR is detected in other cells of epithelial origin, such as renal podocytes and liver 
hepatocytes. The expression of CAR mRNA is prominent in the liver (Raschperger et al., 
2006). These alternate cellular locations for CAR, its apparent capacity to form hetero-
philic associations (e.g., with JAML), and its potential role in cell signaling indicate that 
CAR can serve other functions in addition to homophilic cell adhesion. 
Although CAR is not detected in endothelial or mesenchymal cells in the adult mouse 




thelial cells, where expression is related to cell density and could be downregulated by 
treatment with cytokines (Carson et al., 1999; Vincent et al., 2004). CAR is detected in 
CD31+ cells in damaged areas of the heart, but not in the endothelium of vessels in un-
damaged tissue (Fechner et al., 2003), suggesting that endothelial CAR expression in vivo 
may be restricted to regions of vessel growth or tissue repair. 
In numerous studies of adenovirus mediated gene delivery, CAR expression has been 
identified as important for adenovirus tropism, and expression of CAR in refractory cell 
lines has enhanced their susceptibility to virus entry (Ross et al., 2003; Kim et al., 2002; 
Miller et al., 1998; Qin et al., 2003; Hemmi et al., 1998; Pearson et al., 1999). Nonethe-
less, it is not clear that the marked adenovirus tropism for mouse liver observed in gene 
therapy experiments reflects CAR expression or other factors, as modified adenovirus 
vectors unable to bind CAR still infect the liver (Mizuguchi et al., 2002). 
Adult human CAR RNA levels are highest in the heart, brain, and pancreas, with signifi-
cant levels in the liver, testis and prostate (Tomko et al., 1997; Bergelson et al., 1998). 
This RNA expression pattern is consistent with the tropism of coxsackievirus B3, which 
infects via the GI tract, and causes myocarditis, cardiomyopathy, meningoencephalitis, 
and pancreatitis. CAR-binding adenoviruses primarily infect the respiratory tract, al-
though these adenoviruses are also a major cause of cardiac inflammation like CVB 
(Bowles et al., 2003). 
Very little CAR is detected on healthy adult skeletal muscle and on lymphocytes (Tomko 
et al., 1997; Bergelson et al., 1998; Fechner et al., 1999). The paucity of CAR expression 
appears to be an important limitation for adenovirus-mediated transduction: lymphocyte- 
and skeletal myocyte-specific CAR expression in transgenic mice notably increases the 
susceptibility of normally resistant tissues. In addition, transgenic mice with ubiquitous 




sues (Wan et al., 2000; Tallone et al., 2001; Nalbantoglu et al., 2001; Hurez et al., 2002; 
Schmidt et al., 2000). 
1.1.4.2 CAR expression in embryonic development 
The heart is the first organ to form during embryonic development in vertebrates. It arises 
through a complex series of morphogenetic interactions involving cells from several em-
bryonic origins (Olson and Srivastava, 1996; MacLellan and Schneider, 2000). The early 
heart developmental process includes formation of the primitive cardiac tube, looping of 
the cardiac tube to the right, and chamber specification and formation. Then, during matu-
ration of the fetal heart, cardiomyocytes exhibit two related but distinct modes of growth 
that are highly regulated. The ventricular mass of the fetal heart is augmented by cardi-
omyocyte proliferation, also termed hyperplasia, which decreases progressively in late 
gestation and ceases soon after birth. Increases in cardiac mass postnatally are achieved 
preponderantly through increased cell volume, termed hypertrophy, and not by cell proli-
feration, since the cardiomyocytes have permanently exited the cell cycle. These compli-
cated cardiac morphogenetic events must be coordinated by many fine-tuned, as yet un-
identified factors. Changes in these homeostatic factors may contribute to developmental 
anomalies of the heart.  
CAR expression levels change dramatically during development. A rapid downregulation 
of CAR occurs at birth, after which CAR is only sparsely detected in most of these tis-
sues. In the mouse embryo, CAR expression is prominent in the brain, but expression 
levels drop significantly within the first month of life (Honda et al., 2000; Hotta et al., 
2003; Xu and Crowell, 1996). High levels of CAR expression in the new born brain may 
account for the unique susceptibility of new born, but not adult, mice to encephalitis 
caused by CVB (Feuer et al., 2003). In the nervous system of the adult mouse, expression 




which is consistent with adenovirus infection from the lateral ventricles (Tomko et al., 
2000). 
CAR expression in the heart is of particular interest because adenoviruses and coxsackie-
viruses are the most important causes of viral myocarditis. A variety of evidence suggests 
that CAR expression is regulated during cardiac development. In the rat, CAR is highly 
expressed on fetal and newborn but not adult myocardium (Ito et al., 2000), and CAR 
mRNA levels, which are high in the fetus and newborn, are seen to drop significantly in 
the adult (Fechner et al., 2003; Kashimura et al., 2004). It is not certain whether all CAR 
isoforms are regulated in parallel. In the mouse, it is noted that high levels of CAR pro-
tein in the embryonic heart, with expression dropping after birth. With a limited number 
of human autopsy specimens, Bergerson’s lab has detected CAR expression in the hearts 
of human foetuses, but not in hearts of young children or adults, and little or no CAR is 
seen in most human myocardial biopsy specimens (Coyne and Bergelson, 2005). In im-
mature myocardium, CAR appears diffusedly expressed on the cell surface, but on mature 
myocardium, CAR is localized to the intercalated discs that connect myocardial cells end-
to-end (Petrella et al., 2002; Kashimura et al., 2004). Expression on fetal and regenerating 
myocytes may account for the susceptibility of these cells, but not adult skeletal muscle, 
to adenovirus mediated transduction (Nalbantoglu et al., 1999). 
The expression in epithelial cells in kidney, intestine, and liver is not downregulated after 
birth, but the staining in pancreas and the submandibular glands has partially disappeared 
(Raschperger et al., 2006). 
1.1.4.3 CAR expression in disease 
1.1.4.3.1 Cardiac disease and altered CAR expression 
CAR expression on cultured rat cardiomyocytes is upregulated after exposure to cyto-




toimmune myocarditis, suggesting that CAR expression is modulated in response to in-
flammation (Ito et al., 2000). In a rat model of myocardial infarction, CAR protein ex-
pression is increased on damaged myocardium during the recovery phase, suggesting a 
possible role for CAR in tissue remodeling (Fechner et al., 2003). 
In humans, CAR expression is increased in patients with dilated cardiomyopathy, and 
illness of uncertain etiology that sometimes follows viral myocarditis (Noutsias et al., 
2001), but CAR gene mutations are not a major host determinant in the development of 
myocarditis and DCM (Bowles et al., 2002). It is conceivable that some patients are more 
susceptible to viral infections of the heart because they constitutively express high levels 
of myocardial CAR; however, no abnormalities within the CAR gene have so far been 
identified in patients with myocarditis or cardiomyopathy (Bowles et al., 2002). It is also 
possible that, as in the rat infarction model, CAR expression is induced as part of a re-
modeling program. 
1.1.4.3.2 CAR expression is differed in various cancers 
A number of investigators have been interested in using adenovirus vectors in therapeutic 
approaches to cancer. As a result, many tumor samples have been examined for CAR ex-
pression, which has generally been found to correlate with susceptibility to transduction 
(Okegawa et al., 2001; Pearson et al., 1999; Kawashima et al., 2003; Kim et al., 2003; 
Qin et al., 2003; Sachs et al., 2002; Gu et al., 2004; Wang et al., 2006; Korn et al., 2006; 
Abdolazimi et al., 2007; Okegawa et al., 2000). CAR mRNA was expressed at high levels 
in osteosarcoma, Ewing's sarcoma, neurofibroma, schwannoma, squamous cell carcinoma 
lung cancers, small cell lung cancers; at intermediate levels in exostosis, giant cell tumor, 
liposarcoma, synovial sarcoma, malignant peripheral nerve sheath tumor, and hemangi-
oma; at low levels in alveolar soft part sarcoma and desmoids; and inconsistent in adeno-




Of greater interest are reports that in several human cancers, including bladder and pros-
tate carcinoma, and glioblastoma-multiform, CAR expression is down regulated during 
the progression to malignancy (Okegawa et al., 2001; Kim et al., 2003; Sachs et al., 2002; 
Fuxe et al., 2003). In CAR deficient prostate tumor lines, expression of transfected CAR 
results in inhibition of cell proliferation and decreased tumorogenicity in animals (Kim et 
al., 2003; Okegawa et al., 2000). Similar results have been reported for malignant glioma 
cells (Kim et al., 2003). In bladder cancer cells, CAR expression inhibits proliferation, 
and is related to modulations in the activity of the cell cycle regulators p21-CIP and Rb. 
CAR dependent growth inhibition requires the presence of the CAR cytoplasmic domain, 
and is inhibited by a CAR specific antibody that blocks homotypic adhesion. One inter-
pretation of these results is that CAR dependent intercellular recognition results in trans-
mission of a signal that regulates Rb and CIP and results in growth inhibition. In GI ma-
lignancies (esophageal, pancreatic, colorectal and liver cancer), loss of CAR expression at 
cell-cell junction was evident in many tumor samples. A significant correlation between 
CAR expression and histological grade was found, with moderately to poorly differen-
tiated tumors most frequently demonstrating loss or reduction of CAR expression (Korn 
et al., 2006). 
Given CAR’s importance for adenovirus targeting, and its possible function as a tumor 
suppressor in some tumor types, there has been interest in identifying pharmacological 
agents that will upregulate CAR expression. In a variety of carcinoma cell lines, CAR 
expression is increased by inhibitors of MEK activity, and decreased by Raf activation, 
suggesting that CAR downregulation is controlled through the Raf-MEK-ERK signaling 
pathway (Anders et al., 2003). The activation of the CAR gene promoter is modulated by 
histone acetylation, but not by DNA methylation, in urogenital cancer cells (Pong et al., 
2003). The histone deacetylase inhibitor FR901228 also enhances CAR expression, and 




2003; Kitazono et al., 2001). In a recent study, proteasome inhibitor MG-132 can enhance 
CAR expression in the colon carcinoma cell line lovo (Zhang et al., 2008). In addition, 
CAR expression is increased in cells treated with the chemotherapeutic agents cis-
platinum and etoposide (Hemminki et al., 2003). 
 
1.1.5 CAR knockout models  
Various CAR deficient animal models have been generated to gain additional insight into 
its physiological functions.  
A zebrafish model was generated by injection of morpholino antisense oligonucleotides. 
A requirement for CAR in the terminal differentiation of glomerular podocytes and pro-
nephric tubular epithelia was identified. Podocytes differentiate in CAR morphants but 
are not able to elaborate a regularly patterned architecture of foot processes. In the tu-
bules, CAR was required for the apposition of plasma membranes from adjacent epitheli-
al cells but did not appear to be necessary for the formation of tight junctions. Additional-
ly, tubular epithelia lacking CAR were not able to elaborate apical brush border 
microvilli. These results establish a requirement for CAR in the terminal differentiation of 
renal glomerular and tubular cell types (Raschperger et al., 2008). 
The first CAR murine KO model was established by targeting exon 2 and documented 
that CAR deficiency resulted in embryonic lethality associated with cardiac defects. Spe-
cifically, commencing E10.5, CAR-/- cardiomyocytes exhibited regional apoptosis docu-
mented by both histopathologic features of cell death and positive staining for the apop-
totic marker cleaved caspase 3. CAR-/- fetuses invariably suffered from degeneration of 





In a similar CAR deficient mouse model targeting exon 1, embryonic lethality occurred at 
E11.5 and E13.5 of embryonic development with disorientation and reduced density of 
myofibrils. In addition, mitochondria were enlarged and glycogen storage strongly 
enriched. In line with these defects, pericardial edema as a clear sign of insufficient car-
diac function was observed. Developmental abnormalities likely to be secondary effects 
of gene ablation were the persistent singular cardial atrio-ventricular canal and dilatation 
of larger blood vessels such as the cardinal veins. The secondary nature of these defects 
was supported by the fact that CAR was not expressed on cells of the vascular wall. No 
obvious signs for alterations of the histological organization of the placenta were ob-
served. Thus, CAR is required for embryonic heart development, most likely due to its 
function during the organization of myofibrils in cardiomyocytes (Dorner et al., 2005). 
Chen et al. used conditional gene targeting strategies, generated mice with both germline 
and tissue-specific defects in CAR expression. Homozygous germline deletion of CAR 
exon 2 or cardiomyocyte-specific gene deletion at E10 mediated by Cre recombinase ex-
pressed under the control of the cardiac troponin T promoter resulted in death by E12.5. 
Embryos showed marked cardiac abnormalities by E10.5, with hyperplasia of the left 
ventricular myocardium, distention of the cardinal veins, and abnormalities of sinuatrial 
valves. Within the hyperplastic left ventricle, increased numbers of proliferating cells 
were evident; proliferating cardiomyocytes had failed to differentiate and form normal 
trabeculae. The intercellular junctions of CAR-deficient cardiomyocytes were ill formed 
or absent; myofibrils were also poorly organized. When cardiomyocyte-specific deletion 
occurred by E11, mediated by Cre under control of the α-myosin heavy chain promoter, 
animals survived to adulthood and did not have evident cardiac abnormalities. These re-
sults indicate that during a specific temporal window, CAR expression on cardiomyocytes 




Cardiac specific CAR deletion early in embryonic life leads to severe cardiac abnormali-
ties and death in utero. Two independent knockouts targeting either exon 1 or 2 demon-
strated atrioventricular (AV) conduction block developed in the absence of CAR in the 
adult mouse heart separately (Lim et al., 2008; Lisewski et al., 2008). Lim et al. showed 
the prolongation of AV conduction occurred in the embryonic heart of the global CAR 
KO mouse. In the cardiac-specific CAR KO (CAR-cKO) mouse, the loss of connexin 45 
localization to the cell-cell junctions of the AV node but preservation of connexins 40 and 
43 in contracting myocardial cells and connexin 30.2 in the AV node was observed. There 
was a marked decrease in β-catenin and zonula occludens-1 (ZO-1) localization to the 
intercalated discs of CAR-cKO mouse hearts at 8 weeks before the mice developed cardi-
omyopathy at 21 weeks of age. CAR formed a complex with connexin 45 via its PSD-
95/DigA/ZO-1–binding (PDZ-binding) motifs. They concluded that CAR expression is 
required for normal AV-node conduction and cardiac function. Furthermore, localization 
of connexin 45 at the AV-node cell-cell junction and of β-catenin and ZO-1 at the ventri-
cular intercalated disc are dependent on CAR (Lim et al., 2008). 
1.2 CAR is a tight junction protein 
Tight junctions between epithelial cells regulate the selective diffusion of ions, solutes 
and macromolecules across the intact epithelium and serve to divide the apical and baso-
lateral membrane compartments, such as restrict apical/basolateral intermembrane diffu-
sion of lipids. A variety of researches provide evidences that CAR is a component of the 
tight junction (Cohen et al., 2001b). In polarized epithelial cell lines, and in primary hu-
man airway epithelial cells, CAR can be seen both by confocal microscopy and thin sec-
tion electron microscopy, at the apical pole of the lateral membrane, where it co-localizes 
with the cytoplasmic plaque tight junction protein zonula occludens-1 (ZO-1), a PDZ-
domain protein, although the direct complex formation has not been established. CAR 




lecules, and both soluble CAR (Cohen et al., 2001b) and anti-CAR antibodies (Walters et 
al., 2002) disrupt tight junction formation. In addition, CAR precipitates with ZO-1 (Co-
hen et al., 2001b) and other tight junction proteins from lysates of polarized epithelial 
cells. In non-polarized cells, CAR is also localized to sites of intercellular contact, but not 
to tight junctions per se: for example, CAR is present in the intercalated discs of cardi-
omyocytes (Noutsias et al., 2001) and, under some conditions, it may be present in the 
adherens junctions of epithelial cells (Walters et al., 2002). 
The central structure in the tight junctions is a series of intramembranous strands that are 
believed to provide the occlusive contacts that regulate paracellular ion and solute flow 
(Staehelin, 1973; Sasaki et al., 2003). Freeze fracture splites the leaflets of the cell mem-
brane, allowing an enface view of tight junction strands. Although the precise composi-
tion of the strands remains uncertain, SDS freeze fracture replica labeling (SDS-FRL) 
permits one to demonstrate a close association between specific transmembrane proteins 
(such as occludin and claudins) and the intramembranous tight junction strands (Morita et 
al., 1999; Fujimoto, 1995). Using SDS-FRL, it was demonstrated that CAR is localized 
specifically to the tight junctions of primary airway epithelial cells. These data provide 
additional evidence that CAR is a component of the tight junction. 
CAR’s hydrophobic C-terminal peptide resembles peptide motifs known to interact with 
PDZ protein domains, such as those contained within ZO-1 and other membrane asso-
ciated guanylate kinase (MAGUK) proteins (Gonzalez-Mariscal et al., 2000). ZO-1, the 
central structural protein of the tight junction, serves as intracellular scaffold, linking 
transmembrane receptor proteins, cytoskeletal components, and intracellular signaling 
molecules (Cohen et al., 2001b; Itoh et al., 1999; Fanning et al., 1998; Bazzoni et al., 
2000; Fanning et al., 2002). Within the tight junction, ZO-1 is known to interact directly 
with the transmembrane proteins occluding and claudins, as well as with JAM (Ebnet et 




tion of ZO-1 that occurs in CAR-transfected CHO cells (Cohen et al., 2001b); however, it 
is not yet know whether the association between CAR and ZO-1 is direct, or whether it 
involves an unidentified intermediary protein. 
People have used yeast two-hybrid analysis to identify proteins that interact directly with 
the CAR cytoplasmic domain, and have observed possible interactions with several PDZ 
proteins (Sollerbrant et al., 2003; Coyne et al., 2004; Excoffon et al., 2004). A direct inte-
raction between CAR and multi-PDZ containing protein MUPP1 was found. MUPP1 is a 
tight junction associated molecule known to interact with claudins, JAM and TAPP1 
(Hamazaki et al., 2002; Jeansonne et al., 2003; Kimber et al., 2002). TAPP1 is a protein 
implicated in phospatidylinositol signaling. In the vicinity of synpases, MUPP1 binds 
Tech, a RhoA guanine nucleotide exchange factor (GEF), suggested that it also regulates 
RhoA signaling pathways (Estevez et al., 2008). CAR has also been reported to associate 
with a MAGI-1 (Excoffon et al., 2004), a tight junction associated MAGUK known to 
interact with molecules such as β-catenin, RapGEP, synaptopodin, α-actinin 4 and JAM4 
(Dobrosotskaya and James, 2000; Hirabayashi et al., 2003; Ide et al., 1999; Mino et al., 
2000; Patrie et al., 2002). In addition, the C-terminus of both CAR splice isoforms inte-
ract with ligand of Numb-X (LNX) (Sollerbrant et al., 2003), a PDZ protein believed to 
regulate proteolysis in the Notch signaling pathway in the CNS; however, LNXs have not 
been identified as tight junction proteins (Dho et al., 1998). CAR is also able to interact 
with several other proteins, such as harmonin, MAGI-1b, PICK 1 and PSD-95 (Excoffon 
et al., 2004). 
1.3 CAR mediates virus uptake 
Tight junctions are important in the natural defense against invasion by microbial patho-
gens. In order to initiate infection, many pathogens must breach the epithelial barrier to 




Unsuccessful efforts to use viral vectors for therapeutic gene delivery to airway epithe-
lium have led to the recognition that intact epithelium is highly resistant to adenovirus 
infection and adenovirus mediated gene transfer. Efficient gene delivery to epithelium in 
vivo, and to epithelial monolayers in culture, depends on disruptions of intercellular junc-
tions, at least in part because the virus is unable to attach to the epithelial surface recep-
tors when junctions are intact. The importance of receptor accessibility is demonstrated 
by the increased efficiency of infections noted in epithelial cultures engineered to express 
CAR on the apical surface (Davis et al., 2004; Pickles et al., 2000; Walters et al., 2001). 
Nonetheless, many viruses are known to infect by crossing the airway or intestinal epithe-
lium. 
At least three viruses are now known to initiate infection by attaching to receptors within 
the tight junction: both coxsackieviruses and adenoviruses bind to CAR, reoviruses attach 
to JAM (Barton et al., 2001). Because CAR and JAM are normally sequestered within 
junctions, and thus not readily available to viruses at the apical cell surface, it is not clear 
how interaction with CAR and JAM can promote virus infection of epithelial surfaces. 
Viruses may attach to CAR and JAM when intercellular contacts are opened, the receptor 
molecules may sometimes be exposed on the apical membrane, or alternative receptors 
may be required for infection of intact epithelium. It is also possible that viruses cross the 
epithelium by alternative mechanisms, such as transport through intestinal M-cells, which 
do not require infection of the epithelial cells themselves (Clark and Jepson, 2003). 
The crystal structure of the reovirus σ1 protein (the attachment protein responsible for 
interaction with JAM) reveals striking similarity between σ1 and the adenovirus fiber 
knob (Chappell et al., 2002). The structures of the JAM N-terminal domain and of CAR 
D1 (including the surfaces involved in receptor dimerization and virus attachment) are 
also strikingly similar. Because viruses bind with high affinity to these receptors, it is 




ble for junction formation as described in 1.1.2 (although this would require that attach-
ment proteins gain physical access to the sequestered receptors). 
It is reported that adenovirus fibers applied to the basal surface of a polarized epithelial 
monolayer can disrupt intercellular junctions (Walters et al., 2002). Based on this obser-
vation, a model has been proposed in which excess production of adenovirus fiber knob 
leads to the disruption of cellular junctions, thus contributing to virus spread into the air-
way lumen. It is not yet known whether the junctional rearrangements induced by fiber 
knob result directly from interference with CAR dimerization, or whether fiber knob trig-
gers signals that lead to junctional reorganization, which occurs only after 24 hours. In-
flammatory cytokines have marked effects on the integrity of airway tight junctions, and 
it is possible that adenovirus or soluble fiber may disrupt cell-cell junctions by triggering 
a cytokine response (Coyne et al., 2002). 
 
Figure 3: Model of adenovirus and coxsackivirus escape from airway epithelia. CAR does not only mediate 
cell-cell junction via its extracellular Ig domain homodimerization, but also uptakes adenovirus and cox-
sackievirus. CAR (green) is localized on the basolateral membrane below the level of the tight junction seal 
and on basal cells. Once infection is established, adenovirus (blue) and fiber protein (black) are released 
basolaterally. Fiber increases paracellular permeability by competing CAR-mediated cell-cell adhesion. 
This allows adenovirus escape to the apical surface.. Independent from or together with its co-receptor DAF 
(decay accelerating factor/CD55) (yellow), CAR mediates coxsackievirus binding and uptake and escape 
from the infected cells. Figure modified from (Walters et al., 2002), according to the results from (Meier et 




Like adenoviruses, coxsackieviruses also appear limited in their capacity to infect pola-
rized epithelium when the CAR receptor is engaged in intercellular contacts. The CVB 
susceptibility of cells in vitro is clearly related to the measurable presence of CAR (Sha-
fren et al., 1997), so it has been presumed that the tissue tropism of CVB in vivo is related 
to differential expression of the receptor among cell types. The exceptions, however, sug-
gest that the situation is more complicated in vivo. Some tissues, such as liver, with readi-
ly measurable CAR are not associated with significant CVB pathology (Wessely et al., 
2001), and cytoplasmic host proteins may inhibit the ability of CVB to replicate in some 
cells (Cheung et al., 2005). In contrast, CVBs have been documented in cells of some 
organs that have not been reported to express CAR at readily detectable levels (Anderson 
et al., 1996; Mena et al., 1999). However, some coxsackievirus isolates bind to an addi-
tional receptor, the complement regulatory protein decay acceleration factor (DAF/CD55) 
(Shafren et al., 1995). Because of its glycosyl-phosphatidylinositol-linked membrane 
anchor, DAF is sorted to the apical surface of polarized cells, and is thus likely to be ac-
cessible to pathogens in the airway or intestinal lumen. DAF-binding CVB isolates, un-
like those that interact only with CAR, are capable of infecting polarized epithelial mono-
layers; thus, the capacity to bind to DAF may provide these viruses with a mechanism by 
which to cross the epithelium despite the inaccessibility of CAR (Shieh and Bergelson, 
2002). 
1.4 Aim of the study 
CAR is a type I transmembrane protein of the tight junction and intercalated discs, where 
it mediates virus uptake and homotypic cell adhesion through its extracellular Ig-domains. 
The cytoplasmic tail is alternatively spliced and interacts with various adaptor proteins 
that link to signal transduction and endocytosis (Chung et al., 2005; Sollerbrant et al., 




Coxsackievirus B3 (CVB3) infections are frequent causes of human acute myocarditis, 
often resulting in chronic cardiomyopathy with fibrosis and reduced contractile function 
that may progress into terminal heart failure. It has therefore been suggested as a thera-
peutic target to prevent or treat CVB3 induced diseases such as myocarditis and cardi-
omyopathy. So far, the contribution of CAR-mediated virus update to the pathology asso-
ciated with myocarditis and the underlying pathomechanism has not been investigated in 
vivo. In this work, a heart specific knockout mouse model was generated to study the role 
of CAR in viral myocarditis. This also includes the evaluation of the molecular mechan-
ism and potential side effects secondary to the loss of CAR. 
In addition to its role as a gateway for viruses to enter their target cells, it is important to 
understand the physiological functions of CAR. Thus, various CAR deficient animal 
models have been generated to gain additional insight into its role in cell-cell contact 
formation and remodeling (Dorner et al., 2005; Asher et al., 2005b; Chen et al., 2006; 
Lisewski et al., 2008; Anderson et al., 1996; Mena et al., 1999). Although targeting either 
exon 1 or 2 results in cardiac malformation, degeneration, and lethality in mid-gestation 
of the conventional knockouts, the mechanism lead to those defects and physiological 
changes has been remained elusive. With our converted CAR knockout that resulted in 
the complete deletion of CAR in all cells of the organism, we were able to obtain addi-





2.1 Chemicals and reagents 
If not specified otherwise, all chemicals were purchased from GE Healthcare, Fluka, Invi-
trogen, Merck, Roth, and Sigma-Aldrich. Taq Polymerases, nucleic acids (kb ladders) 
were ordered from GE Healthcare, Fermentas GmbH, Invitek, Invitrogen, and Roche. 
2.2 Kits 
Table 1: List of kits used in this thesis 
Kit Producer 
ABI Prism Big Dye Terminator Kit 3.1 Applied Biosystems 
BCA Protein Assay Kit Pierce 
Bradford Protein Assay Bio-Rad 
Easy Pure DNA Purification Kit Biozym 
ENZA Plasmid Mini Prep Kit I Paqlab 
Invisorb Spin Plasmid Mini Kit Invitek 
Nucleo Bond BAC 100 Macherey Nagel 
Prime-It Random Primer Labeling Kit Stratagene 
qPCR MasterMix Plus  Eurogentec GmbH 
RNase-Free DNase Set Qiagen 
RNeasy Mini Kit Qiagen 
RNeasy total RNA isolation kit  Qiagen 
Supersignal West Femto Maximun Sensitivity Substrate Pierce 
Supersignal West Pico Chemiluminescent Substrate Pierce 
Thermoscript First-Strand Synthesis System Invitrogen 
2.3 Solutions 
Table 2: Buffers 
Solution Contents 
10× FA gel buffer 200 mM 3-[N-morpholino] propanesulfonic acid (MOPS), 50 mM 
sodium acetate, 10 mM EDTA, pH 7.0 
1× FA running buffer  1/10 volume 10× FA gel buffer, 250 mM formaldehyde 
1× TAE  10 mM sodium acetate, 1 mM Na2EDTA, 40 mM Tris/HCl, pH 8.0 
1× TE  10 mM Tris/HCl, 1 mM EDTA, pH 8.0 
20× SSC  3 M NaCl, 0,3 M sodiumcitrat pH 7.0 
Agarose loading buffer 50% (v/v) glycerol, 1 mM Na2EDTA,0.1% (v/v) Xylencyanol, 
0.1% (v/v) orange G 
Blocking solution  5% (w/v) skim milk, 0.1% (v/v) Tween 20 in PBS 
Embryo lysis buffer  50 mM KCl, 3 mM MgCl2, 10 mM Tris/HCl, pH 8.9, 0.01% (w/v) 
gelatine, 0.45% (v/v) NP-40,0.45% (v/v) Tween 20 
Fixation solution  4% (w/v) paraformaldehyde in PBS, pH 7.4 
Gitschier buffer 10× 166 mM (NH4)2SO4, 670 mM Tris pH8.8, 67 mM MgCl2, 50 mM 
β-Mercaptoethanol, 67 mM EDTA 





HBSS  5.4 mM KCl, 0.3 mM Na2HPO4, 0.4 mM KH2PO4,4.2 mM Na-
HCO3, 1.3 mM CaCl2, 0.5 mM MgCl2, 0.6 mM MgSO4, 137 mM 
NaCl, 5.6 mM glucose, pH 7.4 
HS-PBS  637 mM NaCl, 2.7 mM KCl, 10 mM Na2HPO4, 2 mM KH2PO4, pH 
7.4 
Kinexus buffer 20 mM MOPS, pH 7.0 (any other buffer at this pH could be substi-
tuted), 2 mM EGTA, 5 mM , 30 mM NaF, 
60 mM ß-glycerophosphate, pH 7.2, 20 mM sodium pyrophosphate 
(Na2P2O7·10H2O), 1 mM sodium orthovanadate (Na3VO4), 1% 
Triton X-100 (can be substituted with 1% Nonidet P-40) 
Laemmli-buffer  50 mM Tris, 1% (v/v) ß-mercaptoethanol, 2% (w/v) SDS, PBS 137 
mM NaCl, 2.7 mM KCl, 4.3 mM Na2HPO4, 10% (v/v) glycerine, 
0.1% (w/v) bromphenolblue, pH 6.8, 1.4 mM KH2PO4, pH 7.4 
Low TE  10 mM Tris/HCl, 0.1 mM Na2EDTA, pH 8.0 
PBS 137 mM NaCl, 2.7 mM KCl, 4.3 mM Na2HPO4×2 H2O, 1.4 mM 
KH2PO4 
PBST  PBS with 0.1% (v/v) Tween 20 
protein lysis buffer Kinexus buffer, 1% Octyl-ß-D-Glucophyranoside (OGP), 1mM 
PMSF, proteinase inhibitor cocktail tablet/10 ml 
SDS-Buffer 1 % SDS, 10 mM Tris-HCl, pH 7.5, 2 mM EDTA, pH 8.0 
SET stock solution 3M NaCl, 0.4M Tris-HCl, pH 7.8, 20 mM EDTA, pH 7.8 
SET solution 0.2×SET, 0.2% SDS 
Stripping solution  2 % SDS, 62.7 mM Tris-Base, 100mM ß-mercaptoethanol, pH 6.8 
TAB lysis buffer 8 M urea, 2 M thiourea, 2% (w/v) SDS, 75 mM DTT, 0.05 M Tris, 
pH 6.8 
Tail buffer 20 mM Tris/HCl, pH 8.0, 5 mM EDTA, pH 8.0, 0.4 M NaCl, 0.2% 
(w/v) SDS, 
TBS  137 mM NaCl, 2.7 mM KCl, 50 mM Tris, pH 7.4 
TBST  TBS with 0.05% (v/v) NP-40 
Transfer buffer  192 mM Tris, 25 mM glycine, 20% (v/v) methanol, pH 8.3 
Trypsin-EDTA (1x) 0.05% (v/v) trypsin, 0.53 mM EDTA 
Washing buffer PBS with 0.02% (v/v) sodium azide 
2.4 Cell culture media 
Table 3: List of media for cell culture 
Solution Contents 
DMEM  With ultraglutamine and 4.5 g/L glucose, From Lonza-Cambrex 
DMEM powder Gibco-Invitrogen 
Fetal Bovine Serum  LOT#41Q2155K, from Invitrogen 
ESGRO culture medium Chemicon 
DMEM culture medium 10% (v/v) FBS, 1% p/s, 90% (v/v) DMEM 
Differentiation solution 20% (v/v) FBS, 1% p/s, 1% NEAA, 0.08mM ß-mercaptoethanol, 
80% (v/v) DMEM 
ES medium 6.7g DMEM powder, 1.2g NaHCO3, add water to 540ml, 6ml 
NEAA, 6ml L-Glutamine, 6ml p/s, 4.2µl ß-mercaptoethanol, 80ml 
FBS, 120µl Lif (ESGRO) 
MC perfusion solution 113 mM NaCl, 4,7 mM KCl, 0.6 mM KH2PO4, 0.6 mM Na2HPO4, 
1.2 mM MgSO4·7H2O, 0.032 mM Phenol Red, 12 mM NaHCO3, 
10 mM KHCO3, 10 mM HEPES, 30 mM Taurin, 10 mM 2,3-
BDM, 5.5 mM Glucose 
MC digestion buffer Perfusion solution with 0.25 mg/ml Liberase Blendzyme 1, 0.14 





MC stop solution 1 Perfusion solution with 10% FBS, 12,5 µM CaCl2 
MC stop solution 2 Perfusion solution with 5% FBS, 12,5 µM CaCl2 
MC plating medium 0,9× MEM with Hanks’ salts and L-glutamine, 5% FBS, 10 mM 
BDM, 100 U/ml Pen/Strep, 2 mM L-glutamine 
MC culture medium 1× MEM with Hanks’ salts and L-glutamine, 5% FBS, 0.1mg/ml 
BSA, 100 U/ml Pen/Strep, 2 mM L-glutamine 
2.5 Antibodies 
Table 4: Antibodies and their working dilutions 
            Dilution  
Antibody Species IF WB Company 
Primary antibody     
α-actin rabbit  1:1000 Sigma 
α-actinin (EA53) mouse 1:1000  Sigma 
α-Tubulin mouse 1:100 1:1000 Oncogene 
ApoA-1 rabbit  1:1000 Biodesign 
β-integrin rabbit  1:1000 Chemicon 
CAR rabbit 1:50 1:1000 Santa Cruz 
Connexin 40 rabbit 1:100 1:1000 Lifespan Bioscience 
Connexin 43 mouse 1:100 1:1000 Chemicon 
Connexin 43 rabbit  1:1000 Sigma 
Connexin 45 mouse 1:100 1:1000 Chemicon 
Connexin 45 rabbit 1:100 1:1000 Zymed 
Cubilin rabbit  1:500 Santa Cruz 
E-Cadherin rabbit 1:500 1:1000 Abcam 
GAPDH mouse  1:2000 ABR 
HCN4 rat 1:200  Abcam 
N-Cadherin mouse 1:500 1:1000 Zymed 
Transthyretin rabbit  1:2000 Proteintech Group, Inc
Vinculin rabbit  1:500 Upstate 
ZO-1 rat 1:100 1:1000 Chemicon 
Secondary antibody     
Alexa Fluor 488 goat 1:500  Invitrogen 
Alexa Fluor 488 donkey 1:1000  Invitrogen 
Alexa Fluor 568 goat 1:1000  Invitrogen 
Alexa Fluor 594 donkey 1:1000  Invitrogen 
Alexa Fluor 633 goat 1:1000  Invitrogen 
Alexa Fluor 647 goat 1:1000  Invitrogen 
Cy3 goat 1:1000  Dianova 
IgG mouse HRP conjugated   1:2000 Calbiochem 
IgG rabbit HRP conjugated   1:5000 GE Healthcare 
 
2.6 Oligonucleotides 
Oligonucleotides for genotyping and sequencing were synthesized by BioTez GmbH. 
Primer and probes for RT-PCR (TaqMan) analysis were ordered from Applied Biosys-
tems as complete gene expression assay or synthesized by BioTez GmbH (sequences 










CAR P1-3 f CCATGCACAGGGTGATCTG 
CAR P1-3 r TGAGACTAAAAACCAGCAGCTTC 
CAR P1-5 f AACCTAGCCATTCAAAAAGAAGG 
CAR P1-5 r CTCCCTAAACCTTGATCGATACC 
CAR SA K f GGGTACCGCAAAGGCAGCTCTTACAAAATA 









Table 7: Primers and probes for TaqMan Assay 
Primers and probes Sequence 
Mouse ANP f TTCTAGGCGCAGCCCCT 
Mouse ANP r GCAGAGCCCTCAGTTTGCTT 
Mouse ANP porbe 6-FAM-ACCCCTCCGATAGATCTGCCCTCTTGAA-TAMRA 
18S RNA f CGCCGCTAGAGGTGAAATTC 
18S RNA r TGGGCAAATGCTTTCGCTC 
18S RNA probe 6-FAM-TGGACCGGCGCAAGACGGAC-TAMRA 
GAPDH mouse 154f GGC AAA TTC AAC GGC ACA GT 
GAPDH mouse 223r AGA TGG TGA TGG GCT TCC C 
GAPDH probe 6-FAM-AGGCCGAGAATGGGAAGCTTGTCATC-TAMRA 
CAR02 f ACTTTGAACGTGCGCCTCAGA 
CAR02 r TGTAATGCCATCGGTCTTGT 
CAR02 probe 6-FAM-CGTACTTGAACTTAGCGGGTGCCA-TAMRA 
IL-1beta f CAACCAACAAGTGATATTCTCCATG 
IL-1beta r GATCCACACTCTCCAGCTGCA 
IL-1beta probe 6-FAMGGTGGGTGTGCCGTCTTTCATTACACAG-TAMRA 
IL-4 f CGCCATGCACGGAGATG 
IL-4 r CGAGCTCACTCTCTGTGGTGTT 
IL-4 probe 6-FAM-TGCCAAACGTCCTCACAGCAACG-TAMRA 
IL-6 f ACAAGTCGGAGGCTTAATTACACAT 
IL-6 r TTGCCATTGCACAACTCTTTTC 
IL-6 probe 6-FAM-TTCTCTGGGAAATCGTGGAAATG-TAMRA 
IL-10 f CCAGAGCCACATGCTCCTAGA 
IL-10 r GGTCCTTTGTTTGAAAGAAAGTCTTC 
IL-10 probe 6-FAM-CTGCGGACTGCCTTCAGCCAGG-TAMRA 
IL-12a f ACTAGAGAGACTTCTTCCACAACAAGAG 
IL-12a r GCACAGGGTCATCATCAAAGAC 
IL-12a probe 6-FAM-AGCTGCCTGCCCCCACAGAAGA-TAMRA 




Primers and probes Sequence 
IL-12b r TCAAAGGCTTCATCTGCAAGTTC 
IL-12b probe 6-FAMTGGGCGGGTCTGGTTTGATGATG-TAMRA 
TNFα-f CATCTTCTCAAAATTCGAGTGACAA 
TNFα-r CCAGCTGCTCCTCCACTTG 
TNFα probe 6-FAM-CCTGTAGCCCACGTCGTAGCAAACCA-TAMRA 
IFNγ f CAGCAACAGCAAGGCGAAA 
IFNγ r CTGGACCTGTGGGTTGTTGAC 
IFNγ probe 6-FAM-AGGATGCATTCATGAGTATTGCCAAGTTTGA-TAMRA 
TGFb1 f GCTCTTGTGACAGCAAAGATAACAA 
TGFb1 r CGCCCCGACGTTTGG 
TGFb1 probe 6-FAM-CCACGTGGAAATCAACGGGATCAGC-TAMRA 
CX30.2 f GACGCGGTGCAGCTACAGT 
CX30.2 r ATGCGGAAGATCAGCATGATC 
CX30.2 probe 6-FAM- CGCTCGTGGGTCGTCTCTGGC-TAMRA 
CX37-2008 f CCCAGGGTGGCCGAAA 
CX37-2008 r ACACATACTGCTTCTTGGATGCA 
CX37-2008 probe 6-FAM-CCCCTAGCCGCCCCAACAGCT-TAMRA 
CX40 f CAGCCTGGCTGAACTCTACCA 
CX40 r CTGCCGTGACTTGCCAAAG 
CX40 probe 6-FAM-CGCTGTCGGATCTTCTTCCAGCCCAG-TAMRA 
HCN4 f GGGTTAAGTCAGCAGGGTTTTG 
HCN4 r GCATCGTCAGGTCCCAGTAAA 
HCN4 probe 6-FAM-ATTATCCACCCCTACAGTGACTTCAGA-TAMRA 
myD88 f CATTGCCAGCGAGCTAATTG 
myD88 r TCTGTAGATAATCGTCAGAAACAACCA 
myD88 probe 6-FAM-AAAGGTGTCGCCGCATGGTG-TAMRA 
LCK f CCTTCAACTTCGTGGCGAAA 
LCK r CGTCCTTACGGCTCAGATTCTT 
LCK probe 6-FAM-AAACAGCCTGGAGCCTGAACCTTGG-TAMRA 
IFNβ1 f AAAACTGAAGACCTGTCAGTTGATG 
IFNβ1 r CCGCCTCTGATGCTTAAAGG 
IFNβ1 probe 6-FAM-CAGAATGAGTGGTGGTTGCAGGCA-TAMRA 
Cublin f CCAGAGCCCGAATGATACCTAT 
Cublin r AAAAACGTGAAGGTAATATGCAGAAC 
Cublin probe 6-FAMTGGGTTGTCAGAACCGATGAGGAATAMRA 
DAF1 f CCAACTCCTCAGAAACCTTCCA 
DAF1 r CACCTGTGTTAGGCTCTCCTTTG 
DAF1 probe 6-FAM-AGTTAAAGTTTCAGCAACCCAGCATGTACCTGTT-TAMRA 
2.7 Appliances 
Table 8: Equipment 
Equipment Company and type 
Air pump AgnTho's, Stellar A30 
Agarose gel system (Mini) Cosmo Bio Co., LTD, Mupid-21 
Anaesthesia unit AgnTho's, Univentor 400 
Blotting system Biorad, Mini Trans. Blot Cell 
Cell culture incubator Binder, APT Line CB 150 
Centrifuge Eppendorf, centrifuge 5804 
Centrifuge for 96 well Plates Sigma, 4K15, Rotor: 09100 
Centrifuge for falcon tubes Sigma, 3K12 
Chemiluminescence and fluores-
cence imaging system 
Fujifilm, LAS-1000 




Equipment Company and type 
Cryostat Leica, Cryocut 3000  
Desktop centrifuge Heraeus, Biofuge/Eppendorf, centrifuge 5417R 
Fluorescent image analyser Fujifilm, FLA-3000 
Gas Routing Switch AgnTho's 
Gel documentation Syngene, GENE GENIUS 
Glass capillary puller Sutter Instrument Inc., P-97 
Heating plate for mouse Föhr Medical Instruments, EHE-3501/280/140/11 
Homogenizer IKA®-Werk, Ultra-Turrax T-8 
Image eraser Raytest 
Light Source Carl Zeiss MicroImaging, Inc, KL 1500 LCD 
Micro conductance pressure catheter Millar-Instruments, Inc., ARIA SPR-719 
Microplate reader Bio Tek, Synergy HT 
Microscope Olympus, CK30/Leica, DMI 6000 B 
Microtome MICROM, HM355S 
MiniVent Ventilator for Mice Föhr Medical Instruments , Model 845 
Patch clamp amplifier HEKA Elektronik, EPC-9 
Paraffin dispensing unit Leica, EG 1140 H 
PCR Machine MJ Research, PTC-200/225 
Photometer GE Healthcare, Ultraspec 2100 pro  
Pipette Gilsen/Eppendorf 
Power supply Biometra, 105BIO-LVD 
Pumper Pharmacia, LKB-Pumpe P1 
Real-time PCR system Applied Biosystems, 7900HT 
Scintilla counter Beckman counter, LS6000SC 
SDS-PAGE system GE-Healthcare, Hoefer Small gel unit 
Sonicator Bandelin, HD 2070 / UW 2070 
Spectrophotometry PeqLab, NanoDrop ND-1000 
Sterile working bench BDK 
Stereomicroscope Leica, MZ75 
Temperature control module Föhr Medical Instruments , TKM-0902 
Temperature sensor Föhr Medical Instruments , Pt-100 
Thermo shaker Eppendorf, Thermomixer comfort 
Tissue processor Leica, TP 1020 
UV cross linker Vilber Lourmat 
UV light pack Olympus, U-RFL-T 
Water bath Haake, DC10 
2.8 Software 
Table 9: List of software used for this thesis 
Software Company 
Adobe Acrobat professional 7.0  Adobe Systems Inc. 
Aida version 3.51.042  Raytest GmbH 
CorelDRAW Graphics Suite 12.0  Corel Corp. 
Delta 2D Decodon 
GraphPad Prism 5.0 GraphPad Software, Inc 
Image J V1.42d Wayne Rasband, NIH 
LSM 5 Image Browser  Carl Zeiss GmbH 
Metamorph 6.2r2  Universal Imaging Corp. 
Microsoft Office 2007 Microsoft 
Photoshop CS2  Adope Systems Inc. 
SeqMan II 4.03  DNAStar Inc. 





All the mice were maintained according to the procedure approved by the Max-Delbrück-
Center (Germany) institutional animal care committee. Mouse strains were maintained on a 






3.1 Molecular biology methods 
3.1.1 DNA preparation 
3.1.1.1 Mouse Tail DNA preparation 
Total genomic DNA for genotyping was extracted from tissue of the tail by overnight (o/n) 
digest with 25µl of 10 µg/ml proteinase K solution in 725µl Tail lysis buffer at 55°C. 
Proteinase K was inactivated by heat shock at 95°C for 10 min. One volume of phe-
nol/chloroform was added, mixed gently with the sample and centrifuged for 5min at 
14,000rpm. The aqueous phase was transferred into a new tube and 2 volumes of 100% 
ethanol were added. The tube was inverted and swirled to mix and precipitate DNA at -
20°C for at least 30min. The DNA was centrifuged down at 14,000rpm for 15 min. The 
supernatant was aspired and washed once with 70% ethanol. The pellet was briefly air-
dried at room temperature (RT) and was then dissolved in 100μl TE buffer.  
3.1.1.2 Embryonic DNA preparation 
Total genomic DNA for genotyping was extracted from embryonic tissue by o/n digest at 
55°C with 50µl embryo lysis buffer (with 5µl of 10µg/ml Proteinase K) solution. Protei-
nase K was inactivated by heat shock at 95°C for 10 min. Digested tissue was diluted and 
utilized directly for polymerase chain reaction (PCR) genotyping. 
3.1.2 PCR based genotyping 
If not mentioned otherwise, all PCR amplification reactions were conducted with the 
thermostable Taq DNA polymerase. 





Soriano PCR (WT: 419bp, primer: P1 5 f & P1-3 r; 3rd lox site: 349bp, primer: P1 3 f & 
P1-3 r; Rec: 251bp, primer: P1 3 f & P1-3 r): 
 Final concentration Volume 
Gitschier buffer (10×) 1× 2.5µl 
DMSO  10% 2.5µl 
dNTP Mix (10 mM) 0.5mM 1.25µl 
Primers (10 µM) 0.2µM 0.5µl each 
BSA (10mg/ml) 0.08mg/ml 0.2µl 
DNA Template 20-50 ng 1-2µl 
Taq Polymerase (5 U/µl) 0.025 U/µl 0.125µl 
to a final of 25µl with dH2O  - µl 
Program: 
step temperature time   
1 93°C 3 min  
2 60°C 5 min  
3 65°C 5 min  
4 93°C 30 sec  
5 60°C 1 min  
6 65°C 3 min step 4-6, 40× 
7 65°C 10 min  
8 10°C ∞   
Cre PCR (480bp): 
 Final concentration Volume 
PCR buffer (10×) 1× 2.5µl 
dNTP Mix (10 mM) 0.5mM 1.25µl 
Primer Cre 800 (10 µM) 0.6µM 1.5µl 
Primer Cre 1200(10 µM) 0.6µM 1.5µl  
MgCl2(50mg/ml) 1.5mg/ml 0.75µl 
DNA Template 20-50 ng 1-2µl 
Taq Polymerase (5 U/µl) 0.04 U/µl 0.2µl 
To a final of 25µl with dH2O  - µl 
Program: 
step temperature time   
1 94°C 2 min  
2 94°C 15 sec  
3 49°C 15 sec  
4 72°C 45 sec Setp 1-4, 35× 
5 72°C 8 min  
6 4°C ∞  
3.1.3 Agarose gel electrophoresis 
After amplification, the PCR reaction mix was loaded with 1/10 volume agarose loading 




rose gel to separate PCR products. Agarose gels were prepared with UltraPureTM agarose 
(Invitrogen), 0.5× TAE, and 0.5µg/ml ethidiumbromide solution. A 1kB DNA ladder was 
used to determine the size of the PCR product. The separation took place in 0.5× TAE 
running buffer for 20 min at 100 volts in an agarose gel chamber Mupid®-ex (Eurogentec 
GmbH). PCR fragments were visualized on a UV unit (U-RFL-T; Olympus) at 312 nm.  
3.1.4 Determination of nucleic acid concentration 
The concentration of nucleic acid was determined by spectrophotometry (Nanodrop ND-
1000), according to the manufacturer’s instructions. 
3.1.5 Generation of the targeting vector 
The targeting vector of CAR KO was generated or converted by Dr. Michael Radke. To 
generate CAR deficient animals the Cre-lox recombination system was used, flanking 
CAR exon 1, which contains the ATG, with lox sites (Fig. 4). After homologous recombi-
nation blastocyst injection of targeted ES-cells was used to obtain knockout animals. The 
neomycin/flp resistance cassette was removed by germline expression of the FLP recom-
binase (Gotthardt et al., 2003).  
3.1.6 DNA Sequencing 
DNA sequencing is a linear extension reaction initiated at a specific site on the template 
DNA by using a complementary oligonucleotide. All sequencing reactions were per-
formed according to the chain termination method from Sanger (Sanger et al., 1977) us-
ing the standard T7 or Sp6 sequencing primers and the ABI Prism Big Dye Terminator 
Kit v3.1 (Applied Biosystems). These reagents are suitable for fluorescence-based cycle 
sequencing reactions on single-stranded or double-stranded DNA templates and on poly-
merase chain reaction fragments. The following PCR sequencing reaction mix was used 




BigDye Terminator v1.1/3.1 Seq. Buffer (5×) 2.0µl  
Big Dye 1µl  
Primer (10 µM)  0.25µl  
DNA Template 5ng/ 100bp 
to a final of 10µl with dH2O - µl 
Program: 
step temperature time   
1 95°C 10 sec  
2 50°C 5 sec  
3 60°C 4 min Setp 1-3, 30× 
4 10°C ∞  
The ABI PRISM® 377 DNA Sequencer (Applied Biosystems) automatically analyzed 
DNA molecules labeled with fluorescent dyes. After samples were loaded onto the sys-
tem’s vertical gel, they underwent electrophoresis, laser detection, and computer analysis. 
Sequences were analyzed with SeqMan II version 4.03 (DNASTAR Inc.). 
3.1.7 Southern blot with genomic DNA 
10-20 µg of genomic DNA were digested with 30 U of restriction enzyme BamHI) in 
40µl total volume overnight at 37°C. The genomic DNA digests were run on a 14×11cm 
0.8% agarose gel with 1× TAE and electrophoresised at 70 volts for approximately 4.5-5 
hours. After photographing the ethidium bromide stained gel beside a fluorescent ruler, 
the gel was depurinated by soaking for 20 min in 0.25N HCl and then denatured in dena-
turing solution (1.5M NaCl, 0.5M NaOH) for 20 min with gentle rocking. The Hybond 
N+ membrane (GE Healthcare) was prewet in deionized water for 20 min. Membrane and 
Whatman paper were shortly soaked in neutralization solution (1.5M NaCl, 0.5M Tris-
HCl - pH 7.0). DNA was transferred to the membrane by traditional capillary blotting o/n. 
The gel/membrane sandwich was disassembled and the membrane was washed in neutra-
lization solution for 5-10 min. The blot was slightly air dried for approximately 30 
seconds to dampness. The blot was UV crosslinked with 120 Joules twice in a UV cros-
slinker (Vilber Lourmat). The membrane was checked under UV light for the transfer 




Healthcare) at 65°C for 1-4 hours in the rolling hybridization tube incubator. The probes 
were labeled with α-32P dCTP (NEG) using Prim-It Random Primer Labeling Kit (Strata-
gene) according to the manufacturer’s instructions. The labeled probes were purified with 
MicroSpin S-300HR columns (GE Healthcare). 1µl labeled probe was used to measure 
the radioactivity with scintilla counter (Beckman counter LS6000SC). The rest of probes 
were denaturized at 95°C for 3min, cooled down on ice, then added into the hybridization 
tube. Final concentration of probe would be 2 million cpm/ml in 10 ml. The membrane 
was incubated at 65°C o/n. On the next day, the membrane was washed with SET solu-
tion, 3 times for 1 hour each. The blot was air dried until slightly damp, wrapped in plas-
tic wrap. Membrane was exposed in Imaging Plate BAS-IP-MS 2300 (Fuji Film) for 4-48 
hours at -70°C. The signals were developed by FLA-3000 Scanner (Fuji Film) with the 
software BASReader 3.14. The images were analyzed with the software AIDA 3.15.  
3.1.8 Total RNA isolation and purification  
To avoid RNase contamination all experiments involving RNA were conducted with fil-
tertips (Starlab). Tissue were dissected in DEPC treated PBS on ice, quick-frozen, and 
stored at -80°C.  
Table 10: The tissue and corresponding amount used for RNA pool 
Adult tissue:  100mg/sample 
Embryonic tissue number per pool:  
Heart:  9 for E9.5, 6 for E10.5, 3 for E11.5 
Brain:  6 for E9.5, 4 for E10.5, 3 for E11.5 
Yolk sac:  3 for each stage 
Tail:  6 for E9.5, 3 for E11.5 
Liver:  6 for E11.5 
To reduce viscosity of lysate and shear genomic DNA, samples were homogenized with 
an Ultra-Turrax T-8 (IKA®-Werk) in 1 ml TRIzol per 100 mg adult tissue sample or 0.5 
ml TRIzol for embryonic tissue. Total RNA was isolated with TRIzol according to the 




er’s recommendations. RNA quality was controlled using the Agilent 2100 Bioanalyzer 
(Agilent Technologies, Inc) and the Agilent RNA 6000 Nano Kit. 
3.1.9 Formaldehyde agarose gel electrophoresis 
100-500 µg of total RNA was separated on denaturing formaldehyde agarose gels to con-
trol quality and possible degradation. RNA was loaded with 5× RNA loading buffer onto 
a 1.2% (w/v) FA gel prepared with 1/10 volume of 10× FA gel buffer, UltraPureTM aga-
rose, and 0.5 µg/ml ethidiumbromide solution. The separation took place in 1× FA gel 
running buffer for 40 min at 100 volts in an agarose gel chamber Mupid®-ex (Eurogentec 
GmbH). Ribosomal RNA was visualized on a UV unit (U-RFL-T; Olympus) at 312 nm. 
The 28S ribosomal RNA from mouse tissue was present with intensity approximately 
twice that of the 18S RNA band. Diffuse bands would have indicated degradation during 
preparation. 
3.1.10 Synthesis of cDNA 
For quantitative real-time polymerase chain reaction (RT-PCR) it was necessary to gener-
ate cDNA. Therefore total RNA was reverse transcribed using the two-step Thermoscript 
first-strand synthesis system according to the manufacturer’s guidelines: 
2µl dNTP Mix (10 mM) 
1µl Random Primer (50 ng/µl) 
1 µg RNA Template 
- µl to a final of 12µl with RNase free dH2O 
RNA and primer were denatured by incubating at 65°C for 5 min. A mastermix was pre-
pared and added to the denatured primer/RNA mix: 
4µl cDNA Synthesis Buffer (5×) 
1µl DTT (0.1 M) 
1µl RNase OUT (40 U/µl) 
1µl DEPC-treated water 
1µl Thermoscript RT (15 U/µl) 
The cDNA synthesis was performed in the PCR-Thermocycler PTC-200 (MJ Research) at 




3.1.11 Real-time PCR 
Quantitative RT-PCR was carried out using the TaqMan® probe-based chemistry (Applied 
Biosystems) on an ABI 7900HT Fast Real-Time PCR System. Primer and probes were 
designed using Primer Express 1.5 (Applied Biosystems) and ordered from BioTez 
GmbH or ordered as TaqMan® Gene Expression Assays from Applied Biosystems. Real-
time PCR amplification reactions were performed using the qPCR MasterMix Plus (Eu-
rogentec GmbH) according to manufacturer’s specifications with 2× TaqMan universal 
PCR master mix, 900 nM primer, and 250 nM probe. Thermal cycling conditions were as 
follows: 
Program: 
step temperature time   
1. Annealing 50°C 2 min  
2. Denaturing 95°C 10 min  
3. Denaturing 95°C 15 sec  
4. Extension 60°C 1 min Setp 2-4, 50× 
5. Storage 4°C ∞  
Data were collected and analyzed with the Sequence Detection System 1.2 or 2.2 soft-
ware (Applied Biosystems). The Comparative CT Method (Δ CT Method) was used as 
described in the User Bulletin 2: ABI PRISM 7700 Sequence Detection System. 
3.1.12 Microarray analysis  
DNA microarray analysis was run for CAR wildtype, heterozygous and knockout hearts 
from E9.5 embryonic heart pools. Hearts were collected as pools according to genotype; 
each pool contained 9 embryonic hearts. DNA microarray methods were applied as stan-
dard protocol described in the manufacturer’s instructions (Affymetrix). Briefly, total 
RNA was extracted from hearts using the RNeasy total RNA isolation kit (Qiagen). The 
preparation quality was assessed by agarose-formaldehyde gel electrophoresis. Labeled 
and defragmented cRNA was hybridized to GeneChip® Mouse Genome 430 2.0 Array 




arrays were washed and stained with streptavidin-phycoerythrin in the Affymetrix Flui-
dics Station 450 and further scanned using the Affymetrix GeneChip Scanner 3000 7G. 
The image data were analyzed with GCOS 1.4 using Affymetrix default analysis settings. 
Raw data from microarray scans were normalized and analyzed by Dr. Herbert Schulz 
from Max-Delbrück-Center. Transcripts absent from all samples were excluded from 
analysis. After normalization, the data was filtered according to the following criteria 
were considered as a valid signal: (a) either WT or KO expression signal value ≥100; (b) 
the “probesets p value” of considered signal <0.05; (c) fold change difference between 
genotypes ≥1.2. Transcripts were defined as differentially expressed only if they passed 
filtering criteria listed above. 
3.2 Cell biology methods 
Primary cell culture was prepared from E9.5, E10.5 and E11.5 knockout, heterozygous, 
and wildtype embryonic tissue or adult knockout and wildtype hearts. 
3.2.1 Isolation of primary mouse embryonic cardiomyocytes 
The pregnant mouse was sacrificed according to the day of the vaginal plug (E9.5 to 
E11.5) by cervical dislocation. The mouse was laid on its back and swabbed with 70% 
ethanol. A cut across the belly was made and the skin was cut away to expose the gut. 
With sterile forceps and scissors, the uterus was dissected out and placed into a petri dish 
with ice-cold sterile PBS. The embryos were isolated from the uterus, and released from 
yolk sacs, then transferred to a second petri dish with ice-cold sterile PBS. The heart was 
scooped out with a pair of forceps (#5 Dumont) or spring scissors and transferred into a 
sterile 1.5ml tube with a sufficient volume of 0.05% Trypsin/EDTA to cover the heart. All 
hearts were incubated at 4°C for 5 to 10 hours or o/n, and then incubated at 37°C for 15 
min. Tubes were centrifuged at 800g for 3 min and the trypsin/EDTA could be removed 




with 10% FBS were added and the heart tissue was dissociated by pipetting through a 
pipette several times. Hearts were plated out 1 heart/well (e.g. E11.5, 24-well plate) and 
incubated at 37°C with 5% CO2 in an incubator (Binder) with water vapor saturated. 
Most of fibroblasts were removed by differential adherence at 37°C for 30min-1h, (this 
step can be skipped for E9.5-E10.0 heart). Cardiomyocytes should attach in 1-3 hours. 
Medium was changed after 16-24 hours for the first time and then every 48 hours. 
3.2.2 Isolation of embryonic fibroblasts 
Pregnant mice were sacrificed by cervical dislocation at the appropriate day after the va-
ginal plug. The uterus was removed and transferred into a petri dish with ice-cold PBS. 
The embryos were dissected of the uterus tissue and head and if possible internal organs 
were removed. Embryos were kept in 100µl trypsin-EDTA solution o/n at 4°C to allow 
trypsin to penetrate the tissue. Using scissors finely mince the tissue. Embryos were di-
gested at 37°C for 10 min after removing excessive trypsin solution. Digestion was 
stopped by adding 5 volumes of feeder medium. Cells were separated by pipetting up and 
down and plated on cell culture dishes and incubated at 37°C. PMEFs should attach and 
begin to divide in 1-3 days. The medium was changed after 2 days. When the cells were 
confluent, usually after 3-4 days, the cultures were ready for freezing. Cells were frozen 
in 10% DMSO at 2×106 cells/vial (labeled P0). Cells were monitored every day and pic-
tures were taken with the camera system from Visitron System GmbH (Model: 2.2.1). 
Media were changed every other day. 
3.2.3 Isolation of epithelial cells from yolk sac 
3.2.3.1 Coating procedures 
Cell culture dishes were coated with rat tail collagen, type 1 (BD Biosciences) at 5µg/cm2 
diluted in 0.02N acetic acid and incubated at RT for one hour. The remaining solution was 




free medium. Plates may be used immediately or may be air dried and stored at 2-8°C for 
up to one week under sterile conditions. 
3.2.3.2 Primary yolk sac epithelial cells preparation 
The yolk sac was taken into DMEM solution and finely minced into small pieces before it 
was moved into enzyme digestion. The tissue and collagenase (500U/ml) mixture were 
incubated in a 37°C shaker for 40min-1hour until the epithelium cells could be observed 
separating from the matrix. The digestion step was stopped and the cells were centrifuged 
down. The pellet was resuspended in DMEM or PBS. Then glass pipe was used to divide 
the cells from the matrix, air bubbles should be avoided. The cell solution was removed to 
a small culture dish at incubated 37°C for 2 hours or longer. The supernatant was careful-
ly collected and moved into a new collagen coated culture dish and incubated at 37°C. 
Culture medium was changed daily. 
3.2.4 Isolation of adult cardiomyocytes 
The mouse was intraperitoneal injected with 0.5cc heparin diluted in PBS to 100IU/ml 
and scarified by cervical dislocation. After sterilization with 70% ethanol, the peritoneal 
cavity and chest were opened. The heart was gently lifted and the pulmonary vessels were 
cut. A cut was made at about 2mm from the aorta entry into the heart. The heart was then 
immediately placed in a 60mm dish containing 10ml perfusion buffer at RT. The heart 
was cannulated, and the aorta was tied to the cannula with a 6-0 silk thread. The perfusion 
was started immediately (3ml/min) with perfusion buffer for 4 min and then switched to 
the MC digestion buffer for 8-10 min at 3ml/min. The ventricle was cut from the cannula, 
gently teased into several small pieces with fine forceps in 2.5 ml MC digestion buffer 
and dissociated through pipette for several times. The cell suspension was transferred to a 
15ml polypropylene conical tube. The plate was rinsed with 2.5 ml of myocyte stopping 




The dissociation was continued until all the large pieces of heart tissue were dispersed in 
the cell suspension. Rod-shaped and round Myocytes were counted using a hemacytome-
ter. After gravity sedimentation for 8-10 min in the 15ml tube, the supernatant was trans-
ferred to a new 15ml tube and centrifuged for 1 min at 180×g. The new pellet was resus-
pended in 5ml myocyte sopping buffer 2, combined with the original sedimented 
myocytes, and adjusted to a total volume of 10 ml with MC stop 2. The combined pellets 
were transferred to a 60 mm nonstick valmark dish and calcium reintroduction was per-
formed (4 min in each step): 50µl 10mM CaCl2, 50µl 10mM CaCl2, 100µl 10mM CaCl2, 
30µl 100mM CaCl2, 50µl 100mM CaCl2. The Myocytes were transferred to a new 15ml 
tube for gravity sedimentation for 8-10 min. The supernatant was transferred to another 
new 15ml tube and centrifuged for 1 min at 180×g. Both pellets were resuspended and 
combined in 5 ml of MC plating medium (1.2mM Ca2+) at 37°C. Rod-shaped and round 
Myocytes were counted again. After calculation, the rod-shaped myocytes were plated 
with a concentration of 25,000 myocytes/ml in a laminin-coated dish. Myocytes were 
incubated for 1 hr for attachment, then the plating medium was removed and unattached 
myocytes were washed away. The myocytes were incubated in MC culture medium at 
37°C, 5% CO2 until use. 
3.2.5 Preparation of cardiac muscle slices and dye coupling studies 
3.2.5.1 Preparation of adult mouse cardiac muscle slices 
Mice hearts at the indicated times were quickly removed after cervical dislocation under 
deep ether anesthesia and transferred to ice-cold oxygenated standard salt solution (SSS) 
containing (mM): 125 NaCl, 4 KCl, 10 glucose, 1.25 NaH2PO4, 25 NaHCO3, 2 CaCl2, 
and 1 MgCl2. Ventricles were longitudinal cut and embedded in 2.5 % low melting tem-
perature agarose (Biozym Scientific, Oldendorf, Germany) at 30°C. The blocks were 
glued to the stage of a vibrating blade microtome (Leica Microsystems, Nussloch, Ger-




The cardiomyocytes were selected according to the following criteria: The dye diffused 
into the initial cell within the first minute. The rectangular shape could be recognized. 
The cell should be localized within a fiber. The fiber displayed apparently regular con-
traction. 
3.2.5.2 Dye coupling studies on adult mouse cardiac muscle slices 
To examine gap junctional coupling slices were transferred into a submerged recording 
chamber. Glass capillaries prepared by a puller (P-97, Sutter Instrument Inc.) were filled 
with 2% (w/v) 6-carboxyfluorescein (Sigma). The pipette resistance was 30-40 MOhm. 
Pipette solution contained 120mM KCl, 4mM NaCl, 5mM glucose, 5mM EGTA, 10mM 
HEPES, 0.5mM CaCl2 and 4mM MgCl2 (pH 7.3). Individual cardiomyocytes were in-
jected with the dye by iontophoretic injection for 4 min taking negative voltage pulses of 
0.8 V (duration 500 ms, 1 Hz) using EPC-9 (HEKA Elektronik). Intracellular communica-
tion was monitored by fluorescence microscopy and optical images were recorded by a 
CCD camera. For fluorescence images filter set 46 was used (Zeiss; Exc. 500/20 nm, FT 
515 nm, Em. 535/30 nm). The area of dye spread was quantified by software BioVision 
(Vision). The investigator was blinded to the genotype. 
3.3 Biochemical methods 
3.3.1 Preparation of total protein extract and quantification 
3.3.1.1 Total protein extract from adherent cells 
Cell culture medium was removed from culture dishes containing about 1×107 to 2 ×107 
cells. The cells were rinsed twice with ice-cold PBS to remove medium. 200μl ice-cold 
lysis buffer was added to 150 mm culture dish (or 100μl lysis buffer to 100 mm culture 
dish). The cells were scraped in lysis buffer, and the cell suspension was collected and 
transferred into a 1.5ml microcentrifuge tube. The cell lysates were sonicated with a soni-




each time with 10-15 second intervals on ice to rupture the cells and to shear nuclear 
DNA. The homogenate was centrifuged at 90,000 × g or more for 30 min at 4°C in a 
Beckman Table Top TL-100 ultracentrifuge. The resulting supernatant fraction was trans-
ferred to a 1.5ml microcentrifuge tube for protein concentration determination before use. 
3.3.1.2 Total protein extract from tissues 
Tissues from adult and embryonic mice were harvested in PBS on ice and snap frozen in 
liquid nitrogen. For total protein extraction, embryonic tissue samples were homogenized 
using a micro mortar and adult tissue samples were homogenized with an Ultra-Turrax T-
8 (IKA®-Werk) in 1ml of lysis buffer per 250 mg wet weight. All samples were treated 
with a sonopuls sonicator SH70G (Bandelin electronic GmbH) at 70% intensity on ice 
until the lysis was completed. Cell debris and nuclei were separated by centrifugation at 
90,000× g for 30 min at 4°C in a Beckman Table Top TL-100 ultracentrifuge. An aliquot 
of the solubilised protein solution was removed for protein quantification and the remain-
ing solution was quick-frozen in liquid nitrogen and stored in aliquots at -80°C. 
3.3.1.3 Protein quantification 
For protein quantification, different methods were utilized. Either a commercial Bradford 
assay (Bio-Rad) or BCA assay (PIERCE) were performed using the protocols from manu-
factures. The protein concentration was determined before the addition of SDS-PAGE 
sample buffer. Bovine serum albumin (BSA) should be used as the protein standard. Pro-
tein concentration was quantified using plastic cuvettes in a spectrophotometer (GE 
Healthcare) at a wavelength of 595 nm in Bradford assay or SynergyHT multi-detection 
microplate reader (BioTek) at a wavelength of 562 nm in BCA assay. To improve accura-
cy each sample was measured in triplicates. The respective lysis buffer was used as the 
blank value. 




The separation of proteins by molecular mass was carried out according to Laemmli’s 
method (Laemmli, 1970). The protein solution was denatured by application of 2× 
Laemmli-buffer, 0.2% (v/v) ß-mercaptoethanol at 95°C for 5 min. Depending on the mo-
lecular mass of the protein, electrophoresis was performed with 6-12% acrylamide gels at 
60-120 volts in a mini gel chamber SE 250 (HoeferTM) in 1× electrophoresis buffer. A pres-
tained protein ladder was applied to estimate the size of the proteins. 
3.3.3 Western blotting 
The SDS protein gel was transferred to a hybond-C extra nitrocellulose-membrane (GE 
Healthcare). Membrane, Whatman 3MM filter paper and fiber pads were equilibrated in 
transfer buffer. The transfer was performed in a Trans-Blot Cell (Bio-Rad) at 70 V for 1 h 
and 40 V for 2 hours while cooling or o/n at 20 V and 4°C. The membrane was stained 
with Ponceau S to confirm the transfer. For immunodetection the membrane was incu-
bated in blocking solution for 60 min and with the specific first antibody diluted in PBS 
with 5% skim milk for 2 h at RT or o/n at 4°C. The membrane was washed 1× with PBST, 
and 2× with PBS for 15 min each. Horseradish peroxidase-conjugated goat anti-rabbit 
IgG (GE Healthcare), goat anti-mouse IgG (Calbiochem), and donkey anti-goat IgG (San-
ta Cruz Biotechnology, Inc.) were used as the secondary antibodies diluted 1:2000 in PBS 
with 5% skim milk and incubated with the membrane for 60 min at RT. The membrane 
was washed as described above and developed by chemiluminescence staining using ECL 
(SuperSignal West Pico Chemiluminescent Substrate or SuperSignal West Femto Maxi-
mum Sensitivity Substrate, Pierce) according to manufacturer’s instructions. The chemi-
luminescence was detected in an Intelligent Dark Box with a LAS-1000 CCD camera 
(both FUJIFILM). To re-probe the membrane with a different antibody, it was washed 
with PBST, incubated for 30 min at 50°C with stripping solution, washed again with 




absence of the signal. The membrane was blocked again for 60 min before incubating 
with the first antibody. 
3.4 Animal procedures 
3.4.1 Setting up timed matings and dissection 
Timed matings were set up in the afternoon and the morning of detecting a vaginal plug 
was regarded as day 0.5 post conception (E0.5 or 0.5 d.p.c). Pregnant mice were sacri-
ficed following institutional guidelines and the German animal protection law. Embryos 
were harvested at different stages of development. The exact developmental stage of em-
bryos was determined by the number of somites. Whole mount embryos for immunohis-
tology were fixed o/n in freshly prepared 4% PFA in PBS, pH 7.4 at 4°C. In order to pre-
pare protein lysates for expression analysis hearts were dissected in PBS, quick-frozen, 
and stored at -80°C. For RNA studies, hearts were dissected in RNase free PBS and 
treated as described in section 3.1.8. 
3.4.2 Preparation of paraffin sections 
Whole mount embryos were processed through a series of increasing graded alcohol con-
centrations. The embryos were transferred sequentially to 70%, 80%, 90%, 96%, and 
100% ethanol for two hours each. They were then placed in a second 100% ethanol solu-
tion to ensure that all water was removed. Xylol was used as clearing agent 2× for 20 
min. Embryos were embedded either sagittally or transversally and 5μm sections were cut 
on the microtome HM355S (MICROM). Up to 6 sections were placed on 3-aminopropyl-
triethoxysilane (APTEX) coated slides and stored at RT. 
3.4.3 Immunoperoxidase staining 
PFA fixed and paraffin embedded tissue sections were baked at 60°C for 1h, then deparaf-
finized in xylenes/graded ethanol and rinsed in PBS twice. Antigens were unmasked by 




cooled down in the buffer for approximately 20 min and washed in ddH2O 3× for 2 min 
each. Excess liquid was aspirated from slides. Specimens were incubated for 1 hour in 
goat blocking serum in PBS and then incubated with primary antibodies for 30 min at RT 
or o/n at 4°C. Optimal antibody concentration was determined by titration and listed in 
table 4. Unbound antibodies were removed by washing three changes of PBS for 5 min 
each. After incubation with biotin-conjugated secondary antibody diluted in PBS with 1.5% 
normal blocking serum for 30 min, excess secondary antibody was washed away with 
PBS. Then ABC Elite reagent (Vector Laboratories, Burlingame, CA) were used, sections 
were developed with DAB kit (Dako, Glostrop, Denmark) and counterstained with hema-
toxylin (Sigma-Aldrich, Germany) according to manufacturer’s instructions. Specimens 
were dehydrated through alcohols and xylenes, mounted with permanent mounting me-
dium and covered with a glass coverslip. Pictures were taken by a light microscope (Leica 
DMI 6000B). 
3.4.4 H&E staining 
Before staining of the sections, all traces of wax had to be removed with two incubation 
steps in xylol for 5 min. The sections were rehydrated sequentially in 100%, 96%, 90%, 
80%, 70% ethanol, and H2O for 5 min. The staining of the nuclei was performed with 
20% Mayer’s haemalaun solution (Merck) for 1 min then developed under the running tap 
water for 5 min. The cytoplasm and connective tissue were counterstained pink with 1% 
eosin solution for 2 min. Stained sections were dehydrated through a series of increasing 
graded alcohol concentrations (70%, 80%, 90%, 96%, and 100%) and cleared 2× with 
xylol for 5 sec before mounting with canada balsam (Merck) and cover slips. Multiple 
serial sections were analyzed for each developmental stage and genotype on the CK30 





3.4.5 PAS staining 
Sections were brought to water via xylene and ethanol. Sections were placed into 1% pe-
riodic acid for 10-30 min. After rinsing 3× with distilled water, the sections were well 
washed under running tap water and transferred into Schiff's reagent for 10-30 min. Then 
Schiff’s reagent was washed off with distilled water and the sections were washed with 
tap water for about 10 min. Slides were counterstained with Mayer's hemalum for 2 min 
then developed with tap water until hemalum was blued. Dehydration and mounting steps 
were same as previously described in section 3.4.3  
3.4.6 Trichrome staining 
Paraffin embedded tissue slides were deparaffinized and rehydrated as described before. 
Tissues were fixed with Bouins solution o/n. Slides were rinsed under running tap water 
for 60 min, and then briefly washed with ddH2O. Nuclei were stained in Weigerts haema-
toxylin working solution for 7 min, then developed under running tap water for 7 min. 
Sections were stained with Biebrich-Scarlet-Acid fuchsin solution for cytoplasma. After 
rinsing with ddH2O, slides were put in phosphotungstic/phosphomolybdic acid working 
solution for 4 min, and then transferred directly into aniline blue for 5 min in which col-
lagen will be stained. Sections were fixated and differentiated in 1% acetic acid, then 
rinsed with ddH2O, dehydrated very quickly through 95% ethanol and 100% ethanol, cla-
rified in xylene and mounted with mounting medium. 
3.4.7 Immunoperoxidase staining 
PFA fixed and paraffin embedded tissue sections were baked at 60°C for 1h, then deparaf-
finized in xylenes/graded ethanol and rinsed in PBS twice. Antigens were unmasked by 
heat treatment with 10 mM sodium citrate buffer, pH 6.0 at 95°C for 5 min. Slides were 
cooled down in the buffer for approximately 20 min and washed in ddH2O 3× for 2 min 




goat blocking serum in PBS and then incubated with primary antibodies for 30 min at RT 
or o/n at 4°C. Optimal antibody concentration was determined by titration and listed in 
table 4. Unbound antibodies were removed by washing three changes of PBS for 5 min 
each. After incubation with biotin-conjugated secondary antibody diluted in PBS with 1.5% 
normal blocking serum for 30 min, excess secondary antibody was washed away with 
PBS. Then ABC Elite reagent (Vector Laboratories, Burlingame, CA) were used, sections 
were developed with DAB kit (Dako, Glostrop, Denmark) and counterstained with hema-
toxylin (Sigma-Aldrich, Germany) according to manufacturer’s instructions. Specimens 
were dehydrated through alcohols and xylenes, mounted with permanent mounting me-
dium and covered with a glass coverslip. Pictures were taken by a light microscope (Leica 
DMI 6000B). 
3.4.8 Preparation of cryosections 
Dissected and fixed embryos were equilibrated with 30% sucrose in PBS for 6 h at RT. 
For cryosections, embryos were embedded sagittally in Tissue Tek® (OCT Compound, 
Vogel) and 5μm sections were cut using the cryostat (Cryocut 3000, Leica) at -20°C to -
25°C and placed on 3-aminopropyl-triethoxysilane (APTEX) coated slides. Slides were 
immediately used for immunofluorescence staining or stored at -20°C. 
3.4.9 Immunofluorescence staining  
3.4.9.1 Immunofluorescence staining of cells 
Cells were washed in PBS and fixed with ice-cold methanol for 15 min at -20°C. After 
washing and permeabilization, cells were blocked with 2% BSA and 1% normal goat se-
rum in PBS for 30min, incubated with primary antibody (diluted in PBS) for at least 1h in 
wet chamber at RT (100µl for each coverslip) and then washed with PBS. Secondary an-
tibody (diluted in PBS) was applied for 30 min at RT in wet chamber. Nuclei were stained 




nofluorescence stained cells were washed with PBS, rinsed with water, mounted with 
fluorescence protecting medium Fluorescent Mounting Medium (DakoCytomation) and 
dried o/n.  
3.4.9.2 Immunofluorescence staining of cryosections 
Prior to staining, sections from PFA perfused animals or embryos were air dried, re-fixed 
with 4% PFA for 15 min, rinsed with PBS, blocked and permeabilized (with 10% goat 
serum, 0.3% Triton X-100, 0.2% BSA in PBS) for 1 hour. Cryosections were incubated 
for 2 hours at RT or o/n at 4°C with primary antibodies in a wet chamber, followed by 
rinsing with PBS. The fluorescent-conjugated secondary antibodies were applied 1:1000 
in PBS. DAPI was used to stain nuclei. Sections were incubated for 2 hours at RT, and 
followed by washing and mounting procedures. 
3.4.10 Tamoxifen injection 
Tamoxifen stock solution was prepared in peanut oil with the concentration of 10mg/ml 
and stored at -20°C in aliquots (Kuhbandner et al., 2000). For the tamoxifen treatment of 
the inducible heart specific CAR KO mice, the dosage of 30mg tamoxifen/kg B.W. was 
used. For neonatal mice, the mice were properly marked and carefully weighted before 
the intraperitoneal injection. The injection started from P6 and lasted for 10 days. For 
adults, only male mice were used for intraperitoneally injection, 5 times per week, for two 
weeks. The hearts were harvested at 2, 3, 3.5, 4, 8, 12 or 14 weeks after the first injection 
started.  
3.4.11 Virus infection 
cDNA-generated CVB3 Nancy (Kandolf and Hofschneider, 1985) was grown and propa-
gated in Vero cells. Stock virus was prepared by 3× freezing and thawing and purified by 




injection with 5 × 104 plaque-forming units (pfu) of purified CVB3 3 months after induc-
tion with tamoxifen. No background specific differences in virus infection between the 
mixed 129SVJ/C57black6 and either parental strain were detected (data not shown). An-
imals were sacrificed at 10 or 28 days post injection with virus (p.i.), non-infected knock-
out and Cre-negative animals were used as controls. Prof. Dr. Karin Klingel and Dr. Mar-
tina Sauter performed virus infection and the following in situ hybridizations in Tübingen 
University. 
3.4.12 In situ hybridization and quantification of CVB3 infection 
CVB3 RNA in paraffinated tissue sections was detected by radioactive in situ hybridiza-
tion. At the indicated time points, tissue samples were fixed in 4% paraformaldehyde/ 0.1 
M sodium phosphate buffer (pH 7.2) and embedded in paraffin for detection of viral RNA 
using α-35S-labeled enterovirus-specific RNA probe as previously described (Klingel et 
al., 1992). Tissue sections were exposed for 3 weeks and counterstained with hematoxylin 
and eosin. The detection of replication is a robust and sensitive method to document virus 
infected cells. Lacking sensitive assays for virus entry in vivo and since CAR has never 
been implied in replication of CVB3, in situ hybridization was considered the best way to 
detect replication as a measure for virus entry dependent on CAR. To quantify the area 
fraction of infection, ImageJ v.14.1k (http://rsb.info.nih.gov/ij) was used as outlined in the 
user manual.  
3.5 Confocal microscopy 
Protein localization was documented using Carl Zeiss Laser Scanning Microscope LSM 5 
Pascal Version 3.0 SP2 with Carl Zeiss PLAN-NEOFLUAR 40×/100× objective lens (1.3 
NA) or beam scanning confocal microscope Leica TCS SP5 equipped with 63× HCX PL 
APO oil immersion objective lens (1.32 NA). Images were exported from the LSM 5 Im-




3.5.1 3D reconstruction 
The confocal microscope pictures of one cardiomyocyte were taken by serial scanning 
from top to bottom. The 3D reconstruction of the dataset was created using the Meta Im-
aging Series Software (Molecular Devices). Each image section was aligned and stacked 
one on top of another to create a three-dimensional volume calculated using the 3D re-
construction tool of Metamorph 7.1.7. 
3.6 Surgical procedures 
3.6.1 Hemodynamic measurements 
The hemodynamic measurements were performed by Dr. Dirk Westermann. The animals 
were anesthetized (thiopental 125 mg/kg i.p.), intubated, and artificially ventilated 
(n=30). As recently described, a 1.4 F microconductance pressure catheter (ARIA SPR-
719; Millar-Instruments, Inc., Texas, USA) was positioned in the left ventricle (LV) for 
continuous registration of LV pressure–volume (PV) loops in an open-chest as described 
previously in a closed-chest model (Westermann et al., 2007). Calibration of the volume 
signal was obtained by hypertonic saline (10%) wash-in technique (Steendijk et al., 
2001). Systolic function was quantified by LV end-systolic pressure (LVP, mmHg) and 
dP/dtmax (mmHg/s) as an index of LV contractility. Diastolic function was measured by 
LV end-diastolic pressure (LVEDP, mmHg) and dP/dtmin (mmHg/s). Global cardiac func-
tion was quantified by the end systolic and diastolic volume (ESV and EDV, µl), ejection 
fraction (EF, %-calculated) and heart rate (HR, beat/min).  
3.6.2 Surface ECG and in vivo electrophysiology studies 
Each mouse was lightly anesthetized with isoflorane (1.6 Vol% isoflorane/air) and ECG 
standard intervals were measured in 6-limb leads as described previously (Royer et al., 
2005) (n=6 for neonates, n=16 for adults) by Dr. Robert Fischer. The severity of the AV 




block first degree is not defined for mouse, the classification was based on the distribu-
tion of PR intervals in the control group of this study (mean + 2×SD). Thus, in adults, PR 
intervals > 48 ms were considered as prolonged. Additional intermittent block of a single 
AV-conduction was classified as AV-block second degree. Third degree (complete) heart 
block was diagnosed when no atrial impulse propagated to the ventricles. 
3.6.3 Arteriovenous (AV) shunt  
Mice at 8 weeks of age were anesthetized with 1% isoflorane and placed supine at 37°C 
on a heating pad. A ventral abdominal laparotomy was performed. The intestines were 
displaced laterally and wrapped with normal saline-soaked sterilized gauze to retain mois-
ture. The aorta and vena cava between the levels of renal arteries and iliac bifurcation 
were then exposed by blunt dissection of the overlaying adventitia. Both vessels were 
temporarily occluded proximal and distal to the intended puncture site. A needle (18 
gauge) held on a plastic syringe was inserted into the exposed abdominal aorta and ad-
vanced through the medial wall into the vena cava to create the shunt. The needle was 
inserted and withdrawn across the medial wall several times through the same hole, to 
ensure the size and presence of the shunt, before it was finally withdrawn from the aorta. 
The ventral aortic puncture site was immediately sealed with a drop of cyanoacrylate (All 
Purpose Instant Krazy Glue®, Krazy Glue) after withdraw of the needle. The sham pro-
cedure was identical except that the vessels were not perforated. 
3.7 Statistics 
For statistical analysis, GraphPad Prism 5.0 software was used. Results are expressed as 
means ± SEM. Statistical significance between groups was determined using the Mann 
Whitney U test for hemodynamic and electrophysiology data. Expression values were 
compared using an unpaired two-tailed t test to assess differences between two groups. 





Both complete CAR KO and adult cardiac specific inducible CAR KO models were es-
tablished. Germline deletion of CAR is embryonic lethal secondary to cardiac malforma-
tion and malformed myofilaments. With the conditional heart specific deletion of CAR in 
the adult mouse, the roles of CAR as a virus receptor were investigated. Loss of CAR can 
prevent CVB3 induced myocarditis and pathological changes in vivo. The cardiac analy-
sis revealed novel physiological functions of CAR that facilitate the evaluation of poten-
tial side effects of a CAR directed antiviral therapy. 
4.1 Generation of the coxsackievirus and adenovirus receptor (CAR) conventional 
and tissue specific conditional knockout model 
 
Figure 4: Outline of the targeting strategy. Exon 1, which contains the translation start, was replaced with 
the floxed exon 1 and the FRT flanked neo-cassette. The neo-cassette was subsequently removed by ger-
mline expression of the FLP recombinase. A conventional CAR KO and an inducible heart specific CAR 
KO using the MerCreMer fusion protein (MCMcre) were generated. Scale bar: 1000bp. neo: neomycin, lox 





The targeting vector for the CAR KO was generated by Dr. Michael Radke in the lab. 
Cre-mediated recombination was used to generate CAR deficient mice. Exon 1 together 
with part of 5’ UTR was replaced with the floxed exon 1 and the FRT flanked neo-
cassette. The neo-cassette was subsequently removed by germline expression of the FLP 
recombinase, which works on FRT site (Fig. 4).  
 
Figure 5: Verification of inducible heart specific CAR KO model. A) PCR based genotyping using the 
primers indicated in Figure 4 was used to detect the fragments corresponding to wildtype (WT), NEO, 3rd-
lox, and RECf allele. The colony was established by mating FLP transgenics (1) to targeted animals (2). 
The resulting double heterozygous animals (3) were used to obtain floxed heterozygous (4) and homozyg-
ous animals (5). B) For Southern blot genomic DNA was digested with BamHI, hybridized with a 600 bp 
PCR product (probe). The 12 kb WT allele and the 4.4 kb RECf allele were used to distinguish wildtype (1), 
knockout (2), and heterozygous animals (3). C) After tamoxifen injections CAR mRNA expression dropped 
to < 10% in KO animals (n=8 for WT, n=15 for KO, *** P≤0.001). D) Protein levels as determined by 
western blot (CAR compared to α-actin) followed at 2weeks (3) and 14 weeks (4) as compared to two sets 
of controls – vehicle (Vh) injected MCM+ (1) or tamoxifen treated MCM- (2) animals. 
To generate the inducible heart specific CAR knockout mice, floxed animals were bred 
with transgenic mice that harbored the heart specific mutant estrogen receptor fusion pro-
tein (MerCreMer) (Peng et al., 2007). MerCreMer is activated by injection of tamoxifen. 
After a 2-week injection regimen (30mg tamoxifen/ kg B.W. /d; 5 injections per week), a 
reduction in CAR mRNA and protein levels was achieved (Fig. 5C, D). After one week of 





Figure 6: Conventional CAR KO leads to embryonic lethality. A) Time course of WT and conventional 
KO embryos from E 9.5 to 12.5. Embryos started to exhibit morphological changes from E10.5 and cardiac 
hemorrhage was often seen in E11.5. After E11.5, embryos went to the progress of resorption. (Size bar: 
500μm). B) Both wildtype (WT) and recombinated signal (Rec) signal could be detected in heterozygous 
animals by PCR genotyping. In KO embryos, only Rec was present. C) Southern blot verificated that in KO 
embryos, only a 3.4kb Rec signal band was detectable. D) TaqMan assay showed CAR mRNA levels re-
duced in heterozygous and absent in KO (n=6, ** P≤0.01; *** P≤0.001). E) Western blot showed the CAR 
protein typically appears as a doublet as 42/46 kDa in WT and heterozygous but not in KO. Blots were re-
probed with an anti-α-actin antibody to confirm equal loading (repeated at least 6 times). 
low levels were maintained as far as we checked for at least 16 weeks. Protein levels were 
determined by western blot followed at 2 and 14 weeks as compared to two control ani-
mals (vehicle injected MCM+ and tamoxifen injected MCM-). α-actin was used as a load-
ing control to confirm the even loading (Fig. 5D).The primers indicated in Figure 4 was 
used to detect the fragments corresponding to wildtype (WT, 419 bp), NEO (536 bp), 3rd-




the 12 kb WT allele and the 4.4 kb RECf allele were used to distinguish wildtype, knock-
out, and heterozygous animals (Fig. 5B).  
The conditional mouse model was converted into a constitutive mouse model. Therefore, 
the animals with floxed exon 1 were crossed with transgenic mice expressing Cre under 
the control of the protamine promoter (The Jackson Laboratory) (Fig. 4). CAR expression 
is undetectable from day E9.5 in KO embryos. PCR analysis of DNA for wild type, hete-
rozygous and homozygous knockout revealed a 419 bp product for wild type allele (WT) 
and a 251 bp band for recombinated allele (Rec) (Fig. 6B). For Southern blot genomic 
DNA was digested with BamHI, hybridized with a 600 bp PCR product (probe). Wildtype 
mice showed a 12 kb hybridization signal while a 3.4 kb signal for the disrupted knockout 
allele presented as expected in Southern blot analysis. Both hybridization signals were 
detected for heterozygous animals (Fig. 6C). TaqMan assay of CAR mRNA expression 
level and Western blots of total embryonic protein on SDS-PAGE confirmed the result 
that the mRNA and protein were undetectable in homozygous knockout embryos (Fig. 
6D, E). 
4.2 CAR is required for the early embryonic development 
4.2.1 Deletion of CAR causes embryonic lethality at midgestation 
So far, not a single homozygous KO was obtained in more than 800 offspring from breed-
ings (CAR+/- × CAR+/-) that should produce theoretically 25% CAR KO animals, suggest-
ing that CAR-/- animals died during embryonic development or shortly after birth.  
To explore when the death occurred, the timed matings were set up between heterozygous 
animals. More than 1000 embryos were examined between the age of E8.5 and E13.5. 
CAR+/+, CAR+/- and CAR-/- embryos showed a proper Mendelian proportion 1:2:1 until 
E9.5. CAR-/- live embryos (indicated by beating heart) started to decrease from E10.5 to 




ready resorbed. Genotyping resorption bodies confirmed the homozygous deletion of 
CAR. These results indicated that germline deletion of the CAR allele resulted in midge-
station lethality around embryonic day 10.5 to 11.5 (Table 11) and resorption from E11.5 
(Fig. 6A). 
Table 11: progeny from heterozygote intercrosses 
d.p.c. +/+ +/- -/- 
E9.5 77 (21.3%) 194 (53.7%) 90 (25.8%) 
E10.5 123 (28.6%) 227 (52.8%) 80 (18.6%) 
E11.5 75 (34.9%) 106 (49.3%) 34 (15.8%) 
E12.5 13 (26.5%) 36 (73.5%) 0 (0%) 
E13.5-15.5 8 (53%) 7 (47%) 0 (0%) 
Number and percentage of live offspring from CAR+/- × CAR+/- matings. d.p.c: days post coitum. 
4.2.2 CAR deficiency causes heart and vessel malformation 
Up to E9.5, there was no obvious difference between WT and KO. Knockout and wild-
type embryos showed proper development of a beating heart. The CAR deficient embryos 
started to show delayed development from E10.5, indicated by the body size of embryos 
(Fig. 6A). Cardiac morphological changes in conventional KO mice were observed after 
E10.5. Cardiac hemorrhage was more frequent in KO embryos (Fig. 6A and Fig. 7B). The 
KO embryonic body was loosely organized and fluffy. Blood leaked out and accumulated 
in the pericardial and peritoneal cavity. The enlarged space inside the pericardium and the 
manifested prominence of the ventricle part were present in E10.5 KO embryos, sugges-
tive of a severe cardiac dysfunction (Fig. 7A). On histological examination, the ventricu-
lar wall was abnormally thickened (Fig. 7C a-d). Endocardial cushion and atrium cham-
ber were enlarged in KO embryos (Fig. 7C). Aorta and cardinal veins were slightly 
enlarged and malformed in KO embryos (Fig. 7C g, h). The atrium wall and the atrioven-
tricular canal are essentially normal. From E11.5 knockout embryos failed to thrive. The 




glycogen storage were observed with trichrome staining (Fig. 7C c, d) or periodic acid 
Schiff’s staining (Fig. 7C e, f). 
 
Figure 7: Morphological changes in conventional KO mice. A) Embryonic analysis showed enlarged 
space inside the pericardium in conventional CAR KO mice at E10.5. Bar, 0.5 mm. B) Cardiac hemorrhage 
was more frequent in KO embryos. Bar, 0.5 mm. C) Histology at E10.5 (H&E a, b, trichrome staining, c, d) 
and E11.5 (Shiffer’s staining, e, f, H&E, g, h) indicated an increase in ventricular wall thickness (a-d). En-
docardial cushion and atrium chamber were enlarged in KO embryos (a-d, e, and f). Aorta and cardinal 
veins were slightly enlarged in KO embryos (g, h). No obvious collagen and glycogen storage change were 
observed. Abbreviations: ach, atrium chamber; vch, ventricular chamber; ec, endocardial cushion; ao, aorta; 
cv, cardinal vein;*, atrioventricular canal. 
4.2.3 Myofibril disorganization in knockout embryonic cardiac cells 
Since the major abnormalities were observed in embryonic heart in CAR deficient ani-
mals, the investigation was focused on the cardiomyocytes. Co-staining CAR with mo-
noclonal antibody α-actinin (a z-disc protein) revealed that myofibril organization disrup-





Figure 8: Embryonic cardiomyocytes staining. A) CAR was dominantly expressed at the cell-cell contact 
between WT cardiomyocytes (green). Myofibers showed normal orientation and striation as stained by anti-
Z disc protein α-actinin in red. No CAR expression was detected in KO. The myofibrils were shortened and 
disorganized in KO heart. B) Co-staining of CAR (red) with α-actinin (green). CAR was expressed along 
the cell-cell contacts in CAR+/+ cells, myofibrils were well organized and the transition between adjacent 
cells were normal. CAR did not express in CAR-/- cells, and the myofibrils were disorganized and the transi-
tion was discontinued between adjacent cardiomyocytes. C) Co-staining of Connexin43 (red) with α-actinin 
(green) revealed that in CAR-/- cells, Cx43 expression was reduced. D) Three examples of CAR-/- cardi-




cardiomyocytes from wildtype E10.5 embryos, the myofibrils were well assembled and 
continuously transitioned between adjacent cardiomyocytes and showed normal striation. 
In contrast, myofibrils of CAR deficient myocytes were more diffuse, shortened and dis-
organized as compared to wildtype (Fig. 8).  
In some individual CAR KO cardiomyocytes, as showed in figure 8D, the Z-discs were so 
narrow that appeared as spotted aggregates instead of striated pattern. 
4.2.4 The structure of ependymal cells in the brain was disrupted 
The ventricles of the brain and the central canal of the spinal cord are lined with epen-
dymal cells. They form tight junctions and control the exchange of substances between 
these nervous tissue and cerebrospinal fluid (CSF) as the blood-CSF barrier. High levels 
of CAR mRNA and protein expression were observed in the embryonic brain. The mRNA 
level at E11.5 is more than 2-fold higher than that in E9.5 (Fig. 18H). From immunofluo-
rescence staining studies of E11.5 embryos, it was found that in wildtype embryos, CAR 
was predominately expressed in ependymal cells and the choroid plexus (Fig. 9A, B). 
While normal ependymal cells formed a simple cuboidal or low columnar epithelium, in 
CAR deficient embryos, the structure of ependymal cells was disrupted and the formation 
was not preserved (Fig. 9C). 
 
Figure 9: CAR expression in brain. A) CAR expression was detected in epithelial cell-cell contacts within 
ependymal cell layer lining the ventricles at E11.5. B) The epithelial cells of choroid plexus also expressed 




4.2.5 Expression levels of connexins and apolipoproteins are altered in the 
embryonic CAR KO heart 
Towards a better understanding of the molecular basis underlying the embryonic lethality 
in CAR KO mouse, microarray analysis was used to compare expression levels between 
wildtype, heterozygous and knockout embryonic heart. Since some of E10.5 embryos are 
already in the progress of resorption, in order to minimize secondary effects, total mRNA 
pools from nine E9.5 hearts of each genotype was used for the microarray experiment. 
Due to the limited sample resource, only one pool was analyzed per genotype. There were 
296 probe sets which represent around 270 genes was significantly changed between ge-
notypes (≥2 fold, 60 of which ≥3 fold). Those genes were annotated and classified ac-
cording to the subcellular localization and function respectively. 39% affected genes were 
localized extracellular and 19% were membrane proteins (Fig. 10A). 20% for the regu-
lated genes were involved in signaling and 17% in metabolism, furthermore, 11% related 
to lipid metabolism (Fig. 10B). The lists of select affected genes are provided in appendix 
(Table 12, 13). 
 
Figure 10: The classification of changed genes according to Affymetrix screen on E9.5 hearts. 296 probe 
sets which represent around 270 genes was significantly changed between genotypes (≥2 fold, 60 of which 
≥3 fold). A) According to the subcellular localization, 39% affected genes were localized extracellular and 
19% were membrane proteins. B) As annotated and classified according to the functions, 20% for the regu-





Microarray results showed dramatic increase of apolipoproteins, such as Apo A-I, Apo B, 
Apo C2 and Apo M, together with the main HDL receptor cubilin. To verify the microar-
ray results, the expression levels of some altered genes were tested using independent 
pools from mouse embryonic heart at E9.5 (3 pools) and E11.5 (1 pool) (Fig. 11). The 
increase of Apo A-I and the corresponding receptor cubilin was confirmed at both stages 
(Fig. 11A, E). While the rest of tested genes did not show altered expression level at E9.5, 
the expression pattern of those genes changed mostly in E11.5 embryonic heart. The 
mRNA levels of the connexins, Cx40, Cx43 and Cx45 were reduced, especially for Cx45 
(>50%) (Fig. 11F). ZO-1 and MUPP-1 mRNA levels were decreased >30%, while Asph 
and N-cadherin levels had relative stable (Fig. 11G). Notably, fos mRNA level had in-
creased more than 100%, and atrial natriuretic factor (ANP) mRNA decreased to 25% 
compared to wildtype (Fig. 11H).  
 
Figure 11: mRNA levels of genes that might be regulated by loss of CAR. A-D) mRNA levels of E9.5 heart 
was analyzed by 3 different pools for each genotype. CAR expression was absent in KO heart, with in-
creased level of Apo A-I and cubilin (A). The expression levels of other genes were largely unchanged (n=3 
per group, *** p≤0.001, all dada was normalized to the expression level of 18S RNA, and the correspond-
ing WT expression level of each gene was set to 1.) E-H) mRNA expression levels of E11.5 heart. Only one 
pool for each genotype was analyzed, hence statistical significance was not able to show. Similar trend of 
Apo A-I and cubilin increase could be observed (A). Connexins, MUPP1, ZO-1, Asph, N-cadherin and ANP 
showed a trend of decrease and fos showed a trend of increase (F-H). Smoc2 expression levels stayed un-
changed in both E9.5 and E11.5 (D, H). (All data was normalized with 18S RNA and WT CAR expression 




The protein changes of several regulated genes were investigated by western blot using 
total protein extracts from whole E10.5 and E11.5 embryos (Fig. 12). Coincident with 
what was observed by qPCR, Cx43 and Cx45 were also reduced at protein level in the 
whole embryo (Fig. 12A) as well as in cardiomyocytes (for Cx43, Fig. 8C). ZO-1, N-
cadherin and Apo A-I did not show any change of total protein expression (Fig. 12A), 
suggesting the change of those proteins might be tissue or organ specific, or there could 
be compensatory expression in other tissues or organs. Especially for Apo A-I, expression 




Figure 12: Western blot of SDS-PAGE extracts of mouse embryos. 
A) CAR expression was diminished in CAR+/- and lost in CAR-/- em-
bryos. Reduction of Cx43 and Cx45 in CAR-/- was observed. N-
cadherin, ZO-1, Apo A-I were not changed in whole embryos. B) Apo 
A-I expression increased in E11.5 than E10.5, but no global change be-
tween genotypes. GAPDH and α-actin were used as loading controls. 
4.3 Cardiac deletion of the coxsackievirus and adenovirus receptor abolishes 
CVB3 infection and prevents myocarditis in vivo 
4.3.1 Tamoxifen predisposes mice to lethal CVB3 induced pancreatitis 
Since CAR deficiency results in embryonic lethality (Dorner et al., 2005; Asher et al., 
2005b; Chen et al., 2006), the conditional knockout approach was used to evaluate CAR 
as a therapeutic target in CVB3 induced myocarditis in the adult heart as described be-
fore. CVB3 readily infects cardiomyocytes in vitro and in vivo (Klingel et al., 1992; Kan-




on CAR for infection (Shafren et al., 1997) was used in this study. After 2 weeks of ta-
moxifen injections, protein levels in the KO were <10% of WT-levels (Fig. 5D). Follow-
ing this approach, CVB3 infection of 3-month old mice with 2x105 plaque-forming units 
(pfu) caused lethality in both tamoxifen injected cardiac knockout animals and the tamox-
ifen injected cre negative littermate controls starting at day 5 after infection (Fig. 13A). 
The underlying pathology was characterized by total necrosis of exocrine pancreatic aci-
nar cells (Fig. 13B). Together with the increased serum levels of pancreatic enzymes and 
markers of gastrointestinal disease, this indicated a fulminant form of acute pancreatitis 
(Fig. 13C). To circumvent the unexpected and severe of the acute pancreatitis, the virus 
load was changed to 5×104 pfu and the time between application of tamoxifen treatment 
and CVB3 infection was separated by 10 weeks. This approach restored survival to 100% 
and enabled us to investigate the effect of CAR on CVB3 induced myocarditis. 
 
Figure 13: Tamoxifen predisposes mice to lethal CVB3 induced pancreatitis. A) CVB3 infection led to 
premature death of tamoxifen pretreated animals. Lethality from day 5 after infection at a dose of 2x105 pfu 
was independent of the genotype (WT vs. KO) and presented only in the CVB3 infected mice (diamonds) , 
(n=23, P≤0.05). B) Hematoxylin/Eosin staining of the control and CVB3 infected pancreas. The CVB3 
infected pancreas of either genotype showed severe acute necrosis of the acinar cells (day 5 p.i.). C) Blood 
chemistry after day 5 revealed signs of acute pancreatitis with increased serum levels of Amylase (Aml), 
Alkaline Phosphatase (AP), Aspartate Aminotransferase (AST), Lipase (Lip), and Gamma-Glutamyl Trans-







4.3.2 Cardiac CVB3 infection can be abolished by eliminating CAR 
 
Figure 14: A) The distribution of replicating virus was visualized by in situ hybridization using a probe 
specific to CVB3. In the wildtype heart about 30% of cardiomyocytes were infected at day 10 p.i. as indi-
cated by the silver grain precipitates (dark signal) reflecting virus RNA (a), while not a single virus positive 
cell could be detected in knockout hearts (b). The extent of infection of other susceptible organs was similar 
in wildtype and knockout mice (c, e vs. d, f). Gut, liver, lung, and kidney were not infected in either KO or 
WT animals (g-n). (Size bar: 50µm). B) Coxsackievirus protein was detected using an antibody directed 
against VP1 with focal expression in myocytes at 10 days after infection only in the WT heart. (Size bar: 
50µm). C) Virus RNA was only present in the wildtype heart at day 10 as determined by TaqMan analysis. 
D) Quantification of CVB3 infection in pancreas and spleen (n=3 per group). At day 10 p.i., the area frac-
tion of infection in pancreas was 52.6% in WT and 58.7% in KO (P=0.36) and in spleen 2% independent of 
the genotype (P=0.87). 
To document that whether elimination of CAR can efficiently block virus uptake into car-
diomyocytes, in situ hybridization was applied to detect virus RNA and immunohisto-
chemistry to visualize CVB3-VP1 protein in single infected cardiac cells. As shown in 
Figure 14, virus replication was detected in the heart, pancreas, and spleen, while small 
intestine, liver, lung, and kidney did not show signs of infection 10 days post intraperito-




tissue sections derived from 20 knockout hearts was detected. In contrast, virus entry and 
replication did not differ between genotypes in spleen or pancreas at day 10 p.i. (Fig. 
14D) and was identical to the published data (Klingel et al., 1996). Hence, in the induci-
ble CAR deficient mice only the heart was protected from virus entry and subsequent 
replication. 
4.3.3 Loss of CAR prevents viral myocarditis 
 
Figure 15: A) After infection with CVB3, wildtype animals showed myocyte necrosis and inflammation 
with infiltration of mononuclear cells, which was not detectable in the CAR knockout animals. B) Trich-
rome staining revealed increased collagen deposition in areas of the cardiac lesion in wildtype animals, but 
not in CAR knockout mice. The fibrotic lesions solidified at day 28 p.i. in the heart of wildtype mice. Size 
bar: 50µm. C, D) After 10 days or 28 days p.i. markers for inflammation such as IL-6, IL-10, and TNFα 
were elevated in either genotype, with high levels in the wildtype animals. E, F) Cardiac mRNA levels of 





In CVB3 infected WT mice, myocyte necrosis and signs of inflammation were manifest, 
as shown by infiltration of mononuclear inflammatory cells at day 10 after infection and 
subsequent fibrosis at day 28 (Fig. 15A, B). In contrast, the CAR deficient knockout 
hearts did not show any significant morphological changes. The protection of CAR defi-
cient hearts from myocarditis was also reflected by the cardiac mRNA levels of the cyto-
kines IL-6, IL-10, TNFα, IFNγ and the T-cell protein LCK with only minor elevations in 
the KO as compared to the marked increased in WT mice (Fig. 15C-F).  
4.3.4 Cardiac function is preserved in CAR deficient mice after CVB3 infection 
 
Figure 16: Effect of CAR deletion and CVB3 infection on cardiac function. Unlike CAR knockout 
animals, contractile function of CVB3 infected WT hearts was reduced as compared to non-infected WT 
control animals. Statistical significance was obtained for contractility (dP/dtmax, B) and ejection fraction 
(D). In contrast, cardiac function was preserved in infected versus control knockout animals (dark bars in A 
through E). Animals were investigated 10 days after CVB3 infection. (n= 30, * P≤0.05; ** P≤0.01). Ves: 




The functional consequences of CAR deficiency were evaluated by conductance catheter. 
Results showed that contractile function was maintained after CVB3 infection of CAR 
KO animals (Fig. 16). While contractile function was impaired in control animals 10 days 
after infection (reduced contractility and ejection fraction and a trend to reduced devel-
oped pressure, cardiac output, and relaxation), CAR KO animals were unaffected. The 
maintenance of systolic (EF, Pmax, dP/dtmax) and diastolic properties (dP/dtmin as a measure 
for active relaxation) in CVB3 infected knockout hearts demonstrated that the elimination 
of CAR did not only prevent structural changes, but also preserved cardiac function after 
infection with CVB3. 
4.3.5 The expression level of CAR’s co-receptor DAF is not changed in KO heart 
 
Figure 17: The expression level of DAF was not changed in CAR KO. CAR RNA (A) and protein levels 
(B) were altered with a strong effect in MCM animals 3 months after the tamoxifen treatment), while the 
expression of the co-receptor DAF was not significantly changed (C). (n=3 per group, ** P≤0.01; *** 
P≤0.001). 
Some coxsackievirus strains, such as CVB3 Nancy applied in this study, bind to an addi-
tional receptor, the complement regulatory protein decay acceleration factor 
(DAF/CD55), (Shafren et al., 1995). To investigate if DAF is regulated as loss of CAR, 
the mRNA expression of DAF was measured. Although DAF is likely to be accessible to 




lium despite the inaccessibility of CAR, the DAF expression level in myocardium was 
neither significantly changed, nor able to make CVB3 accessible to myocardium alone 
without CAR (Fig. 17). 
4.3.6 Factors other than CAR expression levels influence CVB3 distribution in 
target organs 
CAR has been identified important for CVB3 tropism; knowledge of the subcellular loca-
lization, expression pattern and levels of CAR is relevant for virus entry. A survey of 
CAR protein and mRNA expression in various cell types and tissues was carried out. 
CAR is expressed in various cell types. In polarized epithelial cells, CAR was shown lo-
calized in tight junctions of the apical side (Fig. 18A). A similar expression pattern can be 
found in primary cultured yolk sac cells (Fig. 18B, C). On the cell boundary, CAR is par-
tially co-localized with E-cadherin and ZO-1, and cytoskeletal proteins such as α-tubulin 
formed a connected network independent on CAR localization. In primary cultured neu-
rons, CAR is highly expressed (Fig. 18D). In adult liver, CAR expression is different 
from other cell types or typical epithelial tissue. CAR was detected in bile canaliculi and 
it localized more basolateral side of hepatocytes, without showing co-localization with 
ZO-1 (Fig. 18F). In the hepatic artery, CAR was not detected. In adult cardiomyocytes, 
CAR expression was restricted to intercalated discs where it co-localized with Cx43 as 
shown in 3D reconstruction (Fig. 18G). In normal embryos, CAR is dominantly ex-
pressed in cardiac cells (Fig. 8), brain ependymal cells (Fig. 9A, B) and epithelium layer 
of embryos (Fig. 18E). CAR mRNA levels in brain were markedly upregulated during 
development, while downregulated in heart (Fig. 18H). The mRNA was also detectable in 





Figure 18: CAR localization in different cell types. A) Localization of CAR in epithelial cells. B) Co-
localization of CAR and E-cadherin in primary cultured yolk sac epithelial cells. C) In primary cultured 
yolk sac epithelial cells, α-tubulin formed a network independent on CAR localization. D) Co-localization 
of CAR and N-cadherin in primary cultured neuron cells. E) CAR typically expressed at the epithelial layer 
of the embryonic body trunk. F) CAR (green) localized at epithelial cells in adult liver, but not co-localized 
with ZO-1 (red). G) 3D reconstruction of the adult primary cultured cardiomyocyte showed that CAR and 
connexins 43 co-localized at intercalated disc. CAR was stained in green and cell nuclei in blue. Size bar, 
A-F: 50µm, G: 20µm. H) CAR expression distribution in different tissue at E9.5 and E11.5. At E11.5, CAR 
was highly expressed in the brain. 
To relate the distribution of virus infection RNA to CAR expression, CAR mRNA and 
protein levels for all tissues tested were determined (Fig. 19A, B). Not only did CAR ex-




(spleen vs. pancreas), but conversely tissues that were not susceptible such as gut, liver, 
and lung expressed CAR at levels that were 3- to 10-fold higher than cardiac expression. 
 
Figure 19: Expression of CAR in the adult mouse heart, pancreas (pancr), spleen, gut, liver, lung, and kid-
ney (wildtype males at 6 months of age). CAR mRNA (A) and protein levels (B) differed between tissues 
but did not correlate with infectivity of the tissue. Low levels of CAR expression were documented for 
adult heart, spleen, and kidney. CAR mRNA levels differed >10× in pancreas and lung. RNA levels were 
normalized to heart, (n=3). Increased protein expression was confirmed for pancreas, gut, liver, and lung.  
4.4 CAR regulates cardiac conduction and cell-cell communication in neonates 
and adults 
In addition to providing direct genetic evidence that CAR is CVB3 receptor and cardiac 
deletion of CAR can abolish CVB3 infection and prevent viral myocarditis, the potential 
unwanted effects that might be associated with the loss of CAR in the postnatal heart 
should also be also addressed. Despite efficient postnatal depletion of CAR, the cardiac 
inducible KO animals did not show an obvious adult phenotype. This includes the initial 
cardiac assessment by echocardiography that did not show signs of reduced contractile 
function or dilation in the first month after induction with tamoxifen. The routine moni-




that loss of CAR leads to impaired electrical conductance from atrium to ventricle (Li-
sewski et al., 2008). While depolarization and repolarization of the KO-ventricle was 
normal (QRS complex and QT interval), the conduction of the electrical activity from 
atrium to ventricle was disturbed. This is reflected in the prolonged PR interval after in-
duction of the KO and corresponded to a problem at the level of the AV-node. The PR 
conduction time increased with progressive deletion of CAR from as early as 1.5 weeks 
after tamoxifen induction (at a time where CAR protein levels started to decline). The 
prolongation of the PR interval is the hallmark of first degree AV conduction block (AVB 
I°), which could be documented in all KO animals from week 2 after induction. Blocks of 
a higher degree were present from 4 weeks after induction of the CAR KO, including 
partial failure of AV conduction (AVB II°, 25%) or total dissociation of atrial and ventri-
cular rhythms (AVB III°, 37.5%).  
4.4.1 Impaired early development in neonatal CAR KO mice 
CAR showed a high expression level in embryonic stage, and decreased in adult phase. A 
relative higher expression level of CAR is maintained in neonates compared to adults. 
The neonatal mice were investigated to find out if they have similar disturbance of AV 
conduction as adults after tamoxifen treatment. Tamoxifen treatment can cause abortion 
of pregnant female mice, the attempt to induce Cre recombination and produce cardiac 





Figure 20: Heart specific deletion of CAR resulted in lethality and AV block in neonatal mice. A) Lit-
termates comparison of a WT mouse (left) and cardiac specific CAR deficient mouse (right) after tamoxifen 
injection at P15. B) CAR deficiency resulted in premature death of tamoxifen pretreated animals. Lethality 
occurred from day 8 after injection (n=13, * P≤0.05). C) Cardiac deletion of CAR slowed down the body 
weight increase of neonatal mice (n=13, *** P≤0.0001). D) Annotated ECG curve: the PR-interval corres-
ponds to the time between atrial and ventricular depolarization; RR interval corresponds to the heart rate. E-
F) Simultaneous recordings from surface ECG (ECG I/ECG II) were displayed. The KO showed complete 
AV dissociation with prolonged RR interval, which represents slower heart beating rate. G) Quantification 
of the ECG changes in KO and control animals after the 10-day treatment with tamoxifen. Increased RR 
interval and decreased HR and QTendc corresponded to lower heart rate, the immesurable PQ interval in 






Figure 21: Echocardiography evaluation of cardiac specific CAR KO vs. WT after tamoxifen induction. 
Statistical significance was only obtained for body weight (n=3 for WT, n=5 for KO, * P≤0.05). The con-
tractile functions were preserved both in systolic and diastolic properties. Although increased variance was 
increased in KO mice, there was no statistical significance. 
Nevertheless, CAR could be efficiently eliminated from the neonatal mouse heart via in-
jection of tamoxifen to P6 neonates both on mRNA and protein level. Neonatal littermates 
received tamoxifen injections for 10 days individually, and the body weight was recorded 
every day before injection. 8 days after the first tamoxifen injection, nearly 40% of neo-
nates that carried MerCreMer allele started to die and the mortality kept growing after the 




tion in the heart, all of those died mice showed a very strong recombination band. The 
KO mice were manifest smaller and had significant reduction of body weight (Fig. 20A, 
C). The surviving KO animals were sent for ECG analysis that documented severe AV-
nodal IIIº block with immesurable PQ and PR interval, which indicated complete AV dis-
sociation (Fig. 20F, G). The KO animals had a slower heart rate, indicated by prolonged 
RR interval and QTendc (Fig. 20G). 
Similar to the adult KO mice, the echocardiography of neonatal KO mice did not show 
signs of reduced contractile function or dilation, although the variance was increased in 
KO mice (Fig. 21). 
4.4.2 Cell-cell communication is increased in the adult CAR KO heart 
 
Figure 22: Altered cell-cell communication in the CAR KO heart. A) After injection of fluorescein, the 
dye was passed to neighboring cells. Representative cells from KO and control cardiac slices from week 2 
through 4 after induction of the KO were shown. The increased longitudinal and lateral coupling was most 
prominent in cardiac slices at the 4-week-time point. B) Quantification of >200 injections representing 14 
independent hearts documented the significantly increased coupling from week 3 after induction of the KO. 
The area at the end of the 4 min injection period was used to compare cell-cell communication at the indi-
cated times. For each time point, the number of injections and number of animals is provided (injec-
tions/animals). ** P≤0.01; *** P≤0.001, Mann-Whitney test, Scale bar: 100 µm. 
In the absence of a major anatomical or structural defect in adult KO mice, a functional 
approach was used to explore the mechanism underlying the conduction block. To ana-
lyze the activity of gap junctions, which have previously been implied in isolated AV 
conduction disease (Simon et al., 1998; Nikolski et al., 2003) a dye coupling assay was 




tion of coupling in myometrial cells as compared to lucifer yellow (Ciray et al., 1995). 
This assay enabled us to investigate cell-cell communication between cardiomyocytes in 
situ. In parallel with the reduction of CAR protein levels, cellular exchange of the fluo-
rescein dye increased from week 2 to 4 (Fig. 22A, B). The area covered by dye-filled cells 
after 4 min was used to quantify coupling efficiency. While coupling was not significantly 
different between wildtype (WT) and CAR KO cardiomyocytes at week two after initiat-
ing tamoxifen injection, dye spread increased significantly from week 3 (Fig. 22B). 
4.4.3 Altered expression of the cell-cell contact proteins in CAR KO hearts 
Since the dye coupling experiments indicated a problem in cell-cell communication, the 
structure and protein composition of the intercalated discs and the expression and locali-
zation of gap junction proteins was followed. Intercalated discs of CAR KO cardiomyo-
cytes had a normal ultrastructure that did not show widened gaps between cells or in-
creased folding (Lisewski et al., 2008).  
To determine which genes contribute to the development of the AV-block phenotype, pre-
liminary expression profiling data from mouse atria was obtained, that showed the ex-
pected downregulation of CAR (>10fold down in the KO) and suggest a specific role of 
connexin 43 and connexin 45. The expression of other proteins related to arrhythmia such 
as channels, other connexins, and transcription factors was largely unchanged (data not 
shown). The expression analysis was extended to cardiac ventricle (where differences in 
coupling were documented) and revealed that RNA levels of both cell-cell contact and 
adaptor proteins were altered secondary to the loss of CAR (Fig. 23). This includes re-
duced expression of ZO-1, an adaptor protein that binds both CAR and connexins (Cohen 
et al., 2001b; Toyofuku et al., 1998) (Fig. 23A). Expression of connexins was differential-
ly affected in the CAR KO heart. On the mRNA level, Cx45 expression was reduced only 




(Fig. 23B, C). The altered protein levels of Cx45 and Cx43 (both >40% reduction) in KO 
hearts as compared to Cx40, which was unchanged on mRNA level (Fig. 23D), indicated 
a selective effect of CAR on a subset of connexins. Other proteins involved in cell-cell 
junctions, such as β-integrin, vinculin, N-cadherin and E-cadherin, were largely un-
changed (Fig. 23D). 
 
Figure 23: A) After induction of the KO, expression of CAR and its adaptor protein ZO-1 was reduced 
significantly from week 2 and 4, respectively. B) The composition of the gap junction was altered because 
of differential expression of Cx37 (transiently reduced) and Cx40 (transiently increased, albeit not signifi-
cantly). Expression of Cx43 was unchanged. C) Cx45 was the only connexin with RNA levels significantly 
altered late in the progression of the phenotype (reduced from >8w). The adherens junction protein N-
cadherin was unchanged. All expression data were normalized to GAPDH and levels at week 0 (before 
induction) were set to 1. (n=3 per group. * P≤0.05, ** P≤0.01). D) Cardiac expression of Cx40 and Cx45 
was confirmed on the protein level with down-regulation of Cx45 but not Cx40 in animals at >8w after 
induction of the phenotype. GAPDH was used as a loading control. After normalization to GAPDH, Cx45 





4.4.4 Localization of connexin 43 is dependent on CAR 
Protein composition of the intercalated disc was analyzed in isolated cardiomyocytes at 8 
weeks after induction of the phenotype. Co-staining with α-actinin antibodies confirmed 
the proper orientation of the myofilament and connection to the intercalated disc (Fig. 
24A). Although the structure of the intercalated discs was maintained, protein composi-
tion changed in response to the loss of CAR. Protein composition of the intercalated disc 
was analyzed in isolated cardiomyocytes at 8 weeks after induction of the phenotype. 
While expression and localization of the adherens-junction protein N-cadherin was unaf-
fected (Fig. 24B), the localization of the gap junction protein Connexin 43 (Cx43) was 
altered in KO cardiomyocytes 8 weeks after induction (Fig. 24C). Reduced amounts of 
proteins were accumulated in subdomains within the intercalated disc of the KO. Stri-
kingly, the tight junction protein ZO-1 expression and localization at the intercalated disc 
was not markedly altered, although it was reduced on mRNA level (Fig. 24D). Those ob-
servations indicate a functional link between tight and gap junctions, but not between 





Figure 24: Localization of connexin 43 is dependent on CAR. In the absence of CAR, intercalated discs 
were maintained with proper localization of N-cadherin but changes in expression and localization of Cx43. 
A) Staining with anti-CAR and anti-α-actinin antibodies showed the proper localization of CAR in wildtype 
cardiomyocytes and correct orientation of the myofilaments. In knockout cells specific CAR staining was 
reduced to <10% compared to WT cardiomyocytes. B) Staining with anti-CAR and anti-N-cadherin antibo-
dies documented the proper expression and localization of N-cadherin upon deletion of CAR. C) Staining 
with anti-CAR and anti-Connexin43 (Cx43) antibodies revealed that Cx43 expression was reduced in KO 
cardiomyocytes 8 weeks after induction. Residual Cx43 protein was localized in subdomains within the 
intercalated disc. D) Staining with anti-CAR and anti-ZO-1 antibodies showed that CAR was partially co-
localized with ZO-1, while no significant reduction of ZO-1 in KO cells. Comparable results were obtained 




4.5 Heterozygous CAR KO animals appear phenotypically normal but responded 
differentially to volume overload 
In some animal models, haploinsufficiency can also cause changes in phenotype. As in-
vestigated in CAR heterozygous knockout animals, no obvious morphological or physio-
logical changes were observed between wildtype and heterozygous animals in more than 
1000 offspring, and the survival rate was unaffected. A volume overload challenge was 
applied on CAR+/+ and CAR+/- animals to provoke a phenotype. Arteriovenous shunt (AV-
shunt) and sham surgeries were performed on both CAR+/- mice at the age of 8 weeks. 2 
weeks after surgery, the shunt site could still be observed under the ultrasound (yellow 
arrow in Fig. 25A), and the blood flow from artery to the vein at the shunt site could be 
detected by Doppler. The HW/BW ratio in the WT AV-shunt group was significantly in-
creased comparing to sham CAR+/+ (n=4, p<0.01) and sham CAR+/- (n=4, p<0.01) group. 
CAR+/- AV-shunt group showed a trend to increased HW/BW ratio, statistical significance 
was not obtained between genotypes (Fig. 25C). 
 
Figure 25: AV shunt surgery causes an increased HW/BW ratio that does not differ between geno-
types. A) Ultrasound showed at AV shunt site, a blood flow from artery (along the red line) to the vein 
(along the blue line) was indicated by the yellow arrow. B) Sham operated animal does not have AV shunt 
with regular blood flow. C) The HW/BW ratio was significantly increased in CAR+/+ AV shunt mice com-





Since the first identification of the coxsackievirus and adenovirus receptor (CAR) in 
1997, CAR has been widely studied as a virus receptor and as a cell-cell contact protein 
in embryonic development and disease. A CAR loss of function mutant was generated to 
study the role of CAR during embryonic development. With the cardiac-specific inducible 
CAR knockout model, the potential of CAR as a therapeutic target in cardiac disease was 
evaluated.  
The objective of this work is to understand the importance of CAR as a virus receptor in 
vivo and if elimination of CAR is necessary and sufficient to block virus entry and CVB3 
induced diseases such as myocarditis and cardiomyopathy.  
5.1 Characterization of the embryonic lethality 
5.1.1 Differences and similarities of various CAR knockout models 
Knockout technology is widely used to investigate a particular gene of interest and to 
define its function in the live organism. The considerable interest in CAR’s physiological 
function can be appreciated from the fact that in the past three years, five labs have inde-
pendently published four constitutive and five conditional CAR-knockouts that affect 
CAR exon 1 or 2 (Dorner et al., 2005; Asher et al., 2005b; Chen et al., 2006; Lim et al., 
2008; Lisewski et al., 2008).  
All CAR splice variants (including the soluble isoforms) described so far, contain both 
exon 1 and 2 (Dorner et al., 2004; Thoelen et al., 2001b). Thus, loss of the transcription 
start site and translation start codon in the KO of exon 1 (Dorner et al., 2005) versus the 
possible frameshift resulting from the deletion of exon 2 (Asher et al., 2005b; Chen et al., 
2006) should both cause similar phenotypes. Excision of exon 1, which contains the tran-




other CAR KO strategies, the approach in this study developed a beating heart but died 
with 100% penetrance. The failure of getting live offspring from the intercrosses of CAR 
heterozygous mice indicated that CAR is essential for embryonic development. The em-
bryonic lethality of these animals occurred relative earlier (from E10.5) and started the 
process of resorption from E11.5 (Fig. 6A , Table 11), while the targeting exon 2 knock-
outs appeared grossly normal at the stage E10.5 and the resorption process started at E12 
(Asher et al., 2005b; Chen et al., 2006). Differences of genetic background, or alternative 
splicing that might result in a partial rescue of the exon 2 KO could explain those discre-
pancies.  
5.1.2 The cardiac pathology of the conventional CAR KO 
The cardiac pathology caused by CAR deficiency included thoracic hemorrhage and en-
largement of the pericardial space. Only one paper so far showed the signs of regional 
apoptosis in exon 2 KO (Asher et al., 2005b). Apoptosis signals were neither changed in 
Affymetrix results comparing KO and WT nor were any apoptosis proteins such as cas-
pase 3, 8 and 9 detectable with western blot in E11.5 embryos, which coincided with the 
majority of published data. The apoptosis Asher et al observed can be induced by myo-
cardium hypoxia when the embryos are close to death (Sugishita et al., 2004). Another 
possibility is that the embryos they examed might have slight difference between the age, 
since cardiomyocyte apoptosis is prevalent during the remodeling of the embryonic car-
diac development but the intensity of caspase expression is differed from the stages (Ab-
delwahid et al., 1999; Knaapen et al., 2001).  
The heart specific knockout of exon 2 under the control of cardiac troponin T promoter 
resulted in death by E12.5, with hyperplasia of the left ventricular myocardium, distention 
of the cardinal veins and underdeveloped sinuatrial valves (Chen et al., 2006). Similarly, 




enlarged endocardial cushions. Endocardial cushions are a pair of thickened tissue sec-
tions in the embryonic atrial canal. During embryonic development, they meet and fuse to 
form a septum dividing the canal into two channels, which eventually become the atrio-
ventricular orifices. Increased cell proliferation and reduced apoptosis within the cushion 
mesenchyme and endothelium could cause endocardial cushion enlargement as secondary 
effect of CAR deficiency, since CAR is absent in endocardial cushions but proliferation 
was observed in the heart (Chen et al., 2006). Similarly, the major heart phenotypes of 
Noggin mutant embryos are thicker myocardium and larger endocardial cushions. Both 
defects result from increased cell number and can be rescued by halving the gene dosage 
of Bmp4 (Choi et al., 2007). The endocardial cushion enlargement was also reported in 
many other mutants. Protein tyrosine phosphatase (Shp2) mutation Q79R-Shp2 results in 
embryonic lethality by embryonic day 14.5, and mutant mouse embryos have significant-
ly enlarged endocardial cushions in the atrioventricular canal and in the outflow tract ac-
companying with increased ERK activation (Krenz et al., 2008). Overexpression of Wnt-
9a in avian heart results in enlarged endocardial cushions and AV inlet obstruction. Wnt-
9a-mediated cell proliferation in cardiac cushions can be inhibited by the secreted Wnt 
antagonist Frzb (Person et al., 2005). 
Asph (aspartate beta-hydroxylase) also known as Junctin (JCN), is a transmembrane pro-
tein located at the cardiac junctional sarcoplasmic reticulum (SR) and forms a quaternary 
protein complex with the ryanodine receptor, calsequestrin, and triadin in the SR lumen 
of cardiac muscle (Fan et al., 2007; Fan et al., 2008). An increased expression of junctin 
is associated with an impaired Ca2+ homeostasis, and downregulation of junctin is a com-
pensatory mechanism in human heart failure (Gergs et al., 2007). CAR KO showed car-
diac defects such as ventricle hypertrophy and atrium dilation at E11.5 (Fig. 7C) which 




E11.5, suggesting that the reduction of junctin might also be a compensatory effect of a 
failing embryonic heart.  
In the CAR KO heart at E11.5, expression of the atrial and trabecular marker atrial natri-
uretic factor (ANP) was attenuated, indicating a faiure of normal atrial or trabeculae for-
mation (Cayli et al., 2002; Toshimori et al., 1987). Various in vitro models were used to 
gain insight into pathways involved in the hypertrophy response. Both homozygous and 
heterozygous ANP deficient animal models exhibited ventricular hypertrophy (Klinger et 
al., 1999; Sun et al., 2000). Thus, it is reasonable to suspect that the mechanisms of ven-
tricular hypertrophy in CAR KO heart caused by the decreased level of ANP. 
5.1.3 CAR in myofibril organization 
In isolated embryonic CAR KO cardiomyocytes, the disorganization of myofibrils was 
often observed. Co-staining of CAR and α-actinin or α-tubulin did not show a direct link 
between CAR and myofibrils or cytoskeleton proteins. The Z-discs in CAR KO cardi-
omyocytes appeared as spotted aggregates and myofibrils were more diffuse, shortened 
and disorganized (Fig. 8). Such observation is consistent with the previous findings 
(Dorner et al., 2005; Chen et al., 2006) that myofilament bundles in CAR-null mice were 
thinner than those in wildtype embryos (very few >1 μm in width). This disorganization 
did not occur in isolated adult CAR KO cardiomyocytes (Fig. 24), indicating that CAR is 
needed for myofilament organization in embryos but not essential for its maintenance in 
adult cardiomyocytes. The attainment of mature sarcomeres is partially regulated by cell 
adhesion (Shiraishi et al., 1997), myofibrils can be seen to branch and individual myofi-
brils are aligned laterally in register by the intermediate-filament protein desmin (Li et al., 
1997), forming a three-dimensional network that is linked between cells through interca-
lated discs. Adherens junctions serve as anchor site for developing myofibrils, however, 




show any change in either embryos or adults (Fig. 12A, 23D), suggesting that CAR might 
mediate myofilament organization by interacting with other adaptor proteins. 
In the CAR deficient heart, mRNA expression of various apolipoproteins such as Apo A-I 
and its receptor cubilin were increased. Elevated plasma concentrations of apolipoprote-
ins are a risk factor for a variety of atherosclerotic disorders including coronary heart dis-
ease (Marcovina and Koschinsky, 2002; Marcovina et al., 1999; Scanu, 2003). It is re-
ported that Apo A elicits a dramatic rearrangement of the actin cytoskeleton characterized 
by increased central stress fiber formation and redistribution of focal adhesion (Pellegrino 
et al., 2004). In addition to actin cytoskeleton remodeling, Apo A activates a Rho/Rho 
kinase-dependent intracellular signaling cascade that results in increased myosin light 
chain phosphorylation with attendant rearrangements of the actin cytoskeleton (Pellegrino 
et al., 2004). The elevation of Apo A-I in CAR KO cardiomyocytes could be one of the 
reasons for the disorganization of myofilaments. Cubilin is an endocytic receptor in epi-
thelial Apo A-I/HDL metabolism (Kozyraki et al., 1999). It is required for embryonic 
development and is essential for the formation of somites, definitive endoderm and vis-
ceral endoderm (VE) and for the absorptive function of VE including the process of ma-
ternal-embryo transport of HDL (Smith et al., 2006). Although there is no direct evidence 
of cubilin expression in the normal heart, the sudden increased cubilin and apolipoprotein 
mRNA level in CAR deficient heart suggested an aberrance of lipid uptake and cell mem-
brane permeability caused by the elevation of cubilin and Apo A-I. This is possibly a sec-
ondary effect of CAR deficiency, and might be restricted to the heart region, because total 
Apo A-I protein levels did not differ between genotypes. The Apo A-I and cubilin expres-
sion levels are much lower than the other tissues, such as yolk sac (data now shown). The 
differential expression levels in the heart might be concealed by other tissues, where Apo 
A-I and cubilin are highly expressed since the total protein lysate used for Western blot 




ZO-1 directly interacts with actin filaments, it links tight junction proteins to actin cy-
toskeleton(Dejana et al., 2000; Fanning et al., 2002). We suspect that CAR is required for 
myofibril organization by forming a CAR-ZO-1-actin complex. Determining whether 
CAR keeps a force balance against myofibrils and maintains the stability of the complex 
through interactions with ZO-1 could help us have a better understanding of the underly-
ing mechanism.  
5.1.4 CAR is related to gap junctions 
Gap junctions between cardiomyocytes permit the conduction of electrical impulses pass 
through and excitations will spread from an excited cell to cells connected to it. Disrup-
tions of the gap junction molecule connexins often resulted in impaired communication 
and electrical conductance between cells. Both Cx43 and Cx45 protein was decreased by 
>50% in KO heart at E11.5. Cx43 showed diminished and sporadic distribution at cell-
cell contacts in cultured cardiomyocytes (Fig. 8C). The mRNA levels of most connexins 
did not change at E9.5. At E11.5, the protein reduction of Cx43 and Cx45 in KO heart 
was more obvious comparing to the change on mRNA levels. The reduced Cx43 and 
Cx45 in KO heart suggested an abnormal cell-cell communication secondary to the loss 
of CAR. The differential expression of connexins at mRNA and protein level might indi-
cate that CAR might help stabilize connexins in cardiomyocytes.  
The PDZ-domain proteins, such as MUPP1 (Coyne et al., 2004) and ZO-1(Lim et al., 
2008), their mRNA levels were also decreased at E11.5. Both MUPP1 and ZO-1 interact 
with CAR tail via the PDZ-domain (Coyne et al., 2004). In cultured Caco-2 cells, siRNA 
silenced CAR expression leads to the destabilization of the junction and relocalization of 
MUPP1, but does not affect MUPP1 protein expression (Coyne et al., 2004). In CAR KO 
heart, the decreased mRNA levels of MUPP1 might be a secondary response to the desta-




lization and expression are independent of CAR, but correlated with Cx43 in cardiomyo-
cyte (Toyofuku et al., 1998). ZO-1 reduction could be observed both in embryonic and 
adult KO on mRNA levels, but not on protein levels, suggesting that CAR and ZO-1 ex-
pression regulation is not directly correlated. Absence of CAR indirectly cause decreased 
ZO-1 mRNA levels possibly via impaired Cx43 expression. Those observations indicate a 
functional link between CAR and gap junctions.  
5.1.5 CAR in epithelial permeability 
According to its localization, CAR has been suggested to have a role in cell permeability 
(Raschperger et al., 2006). The lack of tight junctions between ependymal cells and cho-
roid plexus allows a free exchange between CSF and nervous tissue (Gotow and Hashi-
moto, 1982) In wildtype embryos, CAR was expressed in ependymal cells, predominately 
at the apical side of the epithelium (Fig. 9). While normal ependymal cells formed a sim-
ple cuboidal or low columnar epithelium, the structure of ependymal cells was disrupted 
and the formation was not preserved in CAR deficient embryos (Fig. 9C), implicating lost 
of tight junctions in ependymal cells and an impaired control of substance exchange be-
tween the epithelium layer. For comparison, CAR mRNA levels of E9.5 and E11.5 em-
bryonic brains were analyzed. While CAR mRNA levels in heart were decreased, signifi-
cant higher levels of E11.5 brain were detected. The results indicated that CAR as a tight 
junction protein, it might play a role in the regulation of epithelial permeability and tissue 
homeostasis in embryonic development. 
5.2 Evaluation of CAR as a therapeutic target in CVB3 induced cardiac disease 
In addition to providing a genetic tool to generate loss of function mutants, the mouse is 
also a suitable animal model to study the role of CAR in CVB3 induced pancreatitis and 
myocarditis, since pathomechanisms and disease progression are similar in human pa-




Viral myocarditis is one of the main causes of acute and chronic heart failure and cox-
sackievirus is one of the important causative agents, which especially in children accounts 
for a significant fraction of cases of terminal heart failure (Feldman and McNamara, 
2000). The disease process is mimicked in CVB3 infected mice with acute myocarditis 
that proceeds to a chronic phase which can ultimately lead to chronic cardiomyopathy 
(Fairweather and Rose, 2007). To efficiently produce surviving heart-specific CAR KO 
animals and generate an adult KO model without a potentially complicating developmen-
tal phenotype, the inducible heart specific KO was established. The tight control of re-
combination by tamoxifen eliminates developmental effects that might arise from the em-
bryonic loss of CAR expression. To establish the animal model the heart specific 
tamoxifen inducible knockout was infected with the cardiotropic CVB3 Nancy strain that 
has been described to produce severe myocarditis in mice (Klingel et al., 1996). Here, this 
study explores the acute response to CVB3 in heart specific CAR KO. 
5.2.1 Tamoxifen treatment aggravates acute pancreatic induced by CVB3 infection 
The efficient control of the MerCreMer transgene with tamoxifen enabled us to reduce 
CAR protein levels to <10%. While the genetics are predictable and produce the desired 
elimination of CAR exon 1 only after tamoxifen induction in the adult, the virus load re-
sulted in an unexpected lethality of >50% of animals starting at day 5 after infection with 
a severe form of acute pancreatitis in both tamoxifen injected knockout and wildtype con-
trol animals. An even stronger lethality has been described for a different strain of CVB3, 
where 4 x103 pfu per mouse resulted in a 50% mortality by day 5 after infection that left 
no survivors by day 7 (Asher et al., 2005a). Acute pancreatitis is not only caused by 
CVB3, but has also been described in the breast cancer patients treated with tamoxifen 
(Kanel et al., 1997). Therefore, we aimed to restore survival by the combination of de-




overlapping effects. Indeed, a reduced virus load of 5x 104 pfu and separation of tamox-
ifen injections and virus treatment by >2 months completely restored survival. 
5.2.2 CAR is necessary but not sufficient for virus entry in the mouse model of 
CVB3 infection 
With CAR deficient animals surviving the applied virus load, we were able to investigate 
the role of CAR in viral myocarditis. CAR has not only been implied in the progression 
of viral myocarditis based on its function as a virus receptor, but various approaches to 
study CAR in vivo have indicated that reduced CAR expression or interference with CAR 
function could affect the disease process. CAR has been implied in the early phases of 
myocarditis with reduced expression of CAR in MyD-88 deficient mice that are partially 
protected from CVB3 induced pathology (Fuse et al., 2005). Although virus load was 
reduced in the MyD-88 knockout cardiomyocytes as compared to the experiments de-
scribed here, it is unclear if this effect can be attributed to the reduced expression of CAR 
or to the concomitantly increased IFN-α. Soluble recombinant CAR has been used as an 
efficient tool to abolish CVB3- mediated myocarditis in mice indicating the importance of 
the CAR-CVB3 interaction in the disease process (Yanagawa et al., 2004). While this 
approach is closer to the application as a therapeutic strategy, its effects can result from 
interaction of soluble CAR with the virus particle, endogenous CAR, or additional extra-
cellular proteins. 
Here, a loss of function approach was used to exclusively investigate CAR in the acute 
phase of CVB3 induced myocarditis. With CAR expression reduced to 10% of WT levels, 
the cardiac tissue was able to completely abolish cardiac pathology in CVB3 infected KO 
mice (Fig. 13). Structural changes were absent as determined by histology and not a sin-
gle infected cardiomyocyte could be detected by in situ hybridization within a total of 20 




As the MerCreMer transgene directs expression of the recombinase exclusively to the 
heart, virus replication is retained in both pancreas and spleen of KO mice. This might 
help explain the increase in TNFα expression that − albeit reduced in comparison of the 
CVB3 infected CAR knockout − the CVB3 infected control heart was 3-fold increased as 
compared to non-infected animals based on cardiac RNA levels. Although CAR expres-
sion has been detected in multiple tissues including heart, brain, pancreas, liver, lung, and 
gut (Fechner et al., 1999; Bergelson et al., 1998; Tomko et al., 2000), the majority of 
those organs from wildtype mice did not show signs of virus infection (gut, liver, lung, 
and kidney). As confirmed on RNA and protein level, these organs do express CAR, at 
levels that exceed cardiac expression in gut, liver, and lung that were nevertheless not 
infected. Failure of virus to enter these cells could derive from the spatial separation of 
the virus and its receptor or the insufficient expression of co-receptors, or intracellular 
adaptor proteins, such as ZO1 and MUPP1 (Shafren et al., 1997; Cohen et al., 2001b; 
Cohen et al., 2001a; Coyne et al., 2004). The cytoplasmic protein expressed in those cells 
can block the virus entry might also lead to the complete immunity to CVB3 infection in 
the heart. The cryoEM reconstruction of full-length CAR-CVB3 complexes shows that 
adjacent CAR molecules, bind to the CVB3 canyon at the same density (He et al., 2001). 
Lacking of sufficient CAR molecules to form this bivalent association of the adjacent 
receptors might cause the failure of CVB3-CAR complex formation offered another poss-
ible reason that a very low-level expression of CAR can prevent cells from virus entry 
and subsequent pathological changes. 
Conversely, low levels of CAR expression as detected in the spleen do not preclude 
CVB3 infection. Unlike the heart, where most cells are CAR-deficient, permissive cells in 
the spleen apparently do express CAR at sufficient levels to become infected. Overall, the 
tissue distribution and expression analysis indicate that CAR is necessary but not suffi-




itself not mediate virus uptake (Milstone et al., 2005). There are DAF binding and non-
binding strains of CVB3, but even the DAF binding variant cannot mediate lytic infection 
without CAR (Shafren et al., 1997). Thus, CAR exerts a dominant effect on virus entry 
that in the KO could not be overcome by DAF. In the CAR KO heart, DAF expression 
was not significantly changed (Fig. 17C) indicating that it does not contribute to the phe-
notype. 
5.2.3 Cardiac function after CVB3 infection 
To verify that CAR deficiency did not only prevent morphological changes associated 
with myocarditis but also retained normal cardiac function, the contractile and elastic 
properties of CVB3 infected and untreated KO and WT animals were analyzed in vivo 
using the conductance catheter. In the acute phase CAR deficient hearts were unaffected, 
while CVB3 infected control hearts showed an impaired contractile function with a sig-
nificant reduction in parameters of systolic function.  
5.2.4 Direct virus-mediated pathology versus a secondary autoimmune component 
in myocarditis 
In addition to documenting the crucial role of CAR for virus entry into the heart in vivo, 
the established animal model provides novel insights into the pathogenesis of CVB in-
duced myocarditis. It has been argued that CVB myocarditis (at least, the chronic phase 
of disease) is autoimmune in nature. As the MerCreMer transgene is not expressed in T-
cells, there is no reason to expect that putative autoreactive T-cells would not be induced 
in the conditional CAR KO. Here it is shown that virus infection of cardiomyocytes is a 
prerequisite for myocarditis and that even as late at 28 days post-infection, the KO-heart 
looks normal. All other susceptible organs can become infected and show the expected 




cardiomyocytes in the disease and argues against a primary autoimmune component in 
pathogenesis. 
So far, various therapeutic approaches to combat CVB3 infection have been proposed 
using CAR-transgenic erythrocytes to redirect and capture virus particles (Asher et al., 
2005a) or soluble CAR to compete with the cell surface receptor (Dorner et al., 2006; 
Yanagawa et al., 2004; Lim et al., 2006). While the former has led to reduced lethality, the 
latter has worked in tissue culture (Goodfellow et al., 2005) but produced inconsistent 
results in vivo either ameliorating or aggravating the disease process in mice (Yanagawa 
et al., 2004; Lim et al., 2006). Based on the findings in this study one could speculate that 
CAR indeed provides a suitable target in the prevention and possible treatment of viral 
myocarditis. 
5.3 CAR and cell-cell communication 
Any strategy that changes its behavior will have to keep in mind the protein’s roles in the 
healthy heart. CAR is not only relevant for virus uptake and cardiac remodeling, but also 
has a previously unknown function in the propagation of excitation from the atrium to the 
ventricle that could explain the association of arrhythmia and coxsackievirus infection of 
the heart. That might be the side effects of loss-of CAR. 
5.3.1 CAR is important in postnatal remodeling 
The switch from myocyte hyperplasia to hypertrophy occurs during the early postnatal 
period (Li et al., 1996). The neonatal phase is a critical period for the transition from em-
bryonic stage to adulthood. During murine neonatal cardiac development and remodeling, 
a marked increase in numbers of cardiac fibroblasts and a resultant decrease in percentag-
es of myocytes in late neonatal development (day 15) is reported (Banerjee et al., 2007). 




day 5 to adult. CAR expression levels did not change till the first week after birth, and 
then gradually decreased after P7 to adult (Kashimura et al., 2004). The relatively high 
level of CAR expression in heart indicated a role of CAR during the transition of myo-
cardial remodeling. Cardiac specific deletion of CAR in the neonatal phase resulted in a 
postnatal lethality with nearly 40% penetrance and significant body weight decrease, sug-
gesting that CAR still keeps similar functions neonatally as in the embryonic stage. The 
decreased body weight might reflect the delayed development caused by the loss of CAR. 
However, due to the differences of individual development and progressive loss of CAR, 
disruption of cardiac expression cannot lead to 100% mortality of CAR KO mice. Those 
surviving mice developed a severe AVB IIIº: a hallmark of complete heart block with no 
apparent relationship between P waves and QRS complexes. It indicated that the impulse 
generated in the atria (typically the SA node on top of the right atrium) does not propagate 
to the ventricles. Furthermore, those mice had a slower heart rate, which displayed as 
prolonged RR interval on ECG recording. 
Recent studies also showed that CAR deficiency causes prolongation of AV conduction 
(Lim et al., 2008; Lisewski et al., 2008), but the deletion did not cause lethality, slowed 
heart rate and body weight reduction as observed in neonatal mice. While increases in 
atrial size could be characterized as secondary to left ventricular dysfunction, accompany-
ing alterations in heart rate or rhythm have been described in other genetic modified 
mouse models. For example, cardiac specific transgenic mouse line expressing activated 
RhoA resulted in atrial enlargement, bradycardia and sinus and AV conduction dysfunc-
tion (Sah et al., 1999).  
Those results indicated that CAR is essential for cardiac conduction system and individu-
al development during the neonatal remodeling phase. A summary of the respective phe-




5.3.2 Cell-cell contacts at intercalated discs are linked to cardiac arrhythmia 
The contractile tissue of the heart is composed of individual cells with highly specialized 
cell-cell contacts that ensure mechanical and electrochemical coupling in the beating 
heart. Communication along the cardiac myofiber is facilitated through the intercalated 
discs, where various types of these contacts interact in a structured network that when 
disturbed can lead to heart disease (Perriard et al., 2003). So far, three types of cell-cell 
contacts have been linked to cardiac arrhythmia in human and animal models related to 
proper function of the intercalated disc: adherens junctions, desmosomes, and gap junc-
tions. Proteins of the adherens junction and the desmosome affect conduction in part indi-
rectly through gap junctions, whose role in the cardiac conduction system is well estab-
lished. Adherens junctions contain transmembrane proteins of the cadherin family and 
interact with the catenins at the cytoplasmic side to provide coupling to the contracting 
sarcomeres (Li et al., 2006). Together with desmosomes, which connect intermediate fi-
laments (mainly desmin) to the cell surface, they mediate force transmission between 
neighboring cardiomyocytes (Li et al., 2006). Gap junctions are clusters of transmem-
brane channels which link the cytoplasmic compartments of adjacent cells and control 
electrical coupling between cardiac myocytes (Peters, 2006). The channels are formed 
from connexins, which are differentially expressed between the specialized cells of the 
electrical conduction system - including sinuatrial and atrioventricular node (largely 
Cx45), atrial cardiomyocytes (Cx40), and the working myocardium (Cx43) (Carson, 
2001). Their differential gating properties facilitate the sequential depolarization of atria 
and ventricle and changes in the protein composition of the gap junction were associated 
with increased propensity to ventricular arrhythmias (Wilhelm et al., 2006; Betsuyaku et 
al., 2006). Cell uncoupling due to the loss of connexins from intercalated discs occurs 
very rapidly in myocardial infarction and could contribute to the increased risk of arr-




In addition to primary defects of connexins, secondary changes that disturb gap junction 
function and assembly can also result in arrhythmia. Thus, altered expression of or muta-
tions in adherens junction proteins, desmosomes, and associated proteins (N-cadherin, β-
catenin, g-catenin, plakophilin-2, desmoplakin) can lead to altered expression of connex-
ins and impaired impulse propagation (Li et al., 2005; Oxford et al., 2007; Gard et al., 
2005; Saffitz, 2005). The results from this thesis indicated that tight junction proteins are 
linked to cardiac function and disease. As a virus receptor CAR was linked to cardiac 
disease through coxsackievirus B3 (CVB3) that can induce myocarditis and ultimately 
dilated cardiomyopathy (Tomko et al., 1997; Bergelson et al., 1997). In addition to virus 
particles, CAR interacts with proteins related to cell-cell contact formation, endocytosis, 
and signal transduction (Fig. 26). In the heart, unlike in epithelial cells, CAR does not 
contribute to the formation of a classical tight junction – in fact the cardiac tight junction 
protein Claudin-5 localizes to the lateral cell border and is (unlike CAR) downregulated 
in heart failure (Mays et al., 2008; Sanford et al., 2005). These findings suggest differen-
tial roles of these tight junction proteins in the heart.  
Thus, proper interplay of all known cell-cell contacts (including the tight junction) deter-
mines the electrical properties of the adult heart. Loss of the tight junction protein CAR 
leads to severe AV block, but leaves the electrical properties of the atrial and ventricular 
myocardium remarkably unaffected. Detailed characterization of the electrical activity of 
KO hearts revealed no difference in atrial depolarization, so that slowed atrial conduction 
as a reason for the delayed AV conduction (increased PR interval) can be excluded. Phy-
siologically, the PR interval is mainly determined by the conduction through the AV node 
followed by the His-Purkinje bundles. As the His-Ventricle (HV) interval was equal in 
CAR KO and control mice, one can conclude that CAR regulates AV conduction directly 





Figure 26: CAR is a multifunctional receptor that interacts with proteins related to cell-cell contact forma-
tion, endocytosis, and signal transduction. a) CAR can hetero- or homodimerize via the extracellular Ig-
domains. The cytoplasmic tail interacts with various PDZ domain proteins, among them ZO-1 (zona occlu-
dens 1) and MAGI1 (membrane associated guanylate kinase, WW and PDZ domain containing 1) that link 
to actin filament assembly. b) The common binding protein ZO-1 mediates interaction between the cytop-
lasmic tails of CAR and connexins to modulate the gap junction activity. c) Together with its co-receptor 
decay accelerating factor (DAF/CD55), CAR mediates virus binding and uptake. d) Links to signal trans-
duction include the interaction of CAR with β-catenin and MUPP1 (multi-PDZ domain protein 1). Both 
CAR and connexins are substrates of tyrosine kinase. 
5.3.3 Cross-talk of tight junction and gap junction 
Towards understanding the molecular mechanism underlying the AV-block phenotype, the 
KO model generated in this study was compared to published animal models with arr-
hythmia that involves prolonged PR-intervals (Lisewski et al., 2008). With the severe AV-
block in the absence of atrial or ventricular arrhythmia mimicked in the Cx45 KO and 
reduced Cx43 and Cx45 expression in embryonic CAR KO heart, one can hypothesize 
that CAR affects electrical conduction indirectly through gap junctions. Since the size of 
the murine AV-node prevents functional studies of the AV-nodal cells, gap junction activi-
ty in cardiomyocytes was investigated as a proof of concept. While dye coupling is wide-
ly used to study gap junctions in cultivated cardiomyocytes (Oxford et al., 2007), the me-




required for intercellular communication. The increased dye coupling from week 3 after 
induction of the KO was shown in Figure 22 indicating crosstalk of the tight and gap 
junction. Thus, CAR might affect conduction through altered compartmentalization of 
connexins. A similar dependence has been shown for N-cadherin and connexins with de-
creased expression of Cx40 and 43 in the N-cadherin KO heart (Li et al., 2005). On a mo-
lecular level the functional interaction of gap and tight junction is supported by coprecipi-
tation and co-localization of Cx40 and Cx43 with tight-junction molecules occludin, 
claudin-5, and ZO-1 in endothelial cells (Nagasawa et al., 2006).  
The increased dye coupling does not lead to altered electrical properties of the atrium or 
ventricle in CAR KO. This indicates that CAR KO cardiomyocytes, unlike AV-nodal 
cells, are not limited by gap junction activity, a feature that could derive both from altered 
expression of connexins and differential localization of CAR between the cell-types. 
Atrioventricular conduction is altered in various connexin KO animals such as the cardiac 
KO of Cx45 (Nishii et al., 2003) or the KO of Cx40, which displays a combination of 
intra-atrial block, ectopic rhythms, and altered atrial propagation in the right atrium 
(Bagwe et al., 2005). None of the ectopic rhythms described in the Cx40 KO or of the 
spontaneous or the inducible ventricular tachyarrhythmias of the Cx43 KO (Danik et al., 
2007) could be detected in the CAR KO heart. These results indicate a residual function 
of Cx40 and Cx43 in the CAR KO and further underscore the specific role of CAR in AV 
conduction. In part, this is reflected in the differential expression of connexins in the KO 
heart: Cx40 protein levels are maintained at physiological levels, while Cx45 expression 
is reduced in the KO heart. Together with the functional analysis indicating that Cx40 or 
Cx45 are affected in CAR KO (both share the AV block phenotype with the CAR KO) the 
expression analysis suggests that the effect of CAR is mediated by Cx45.  
The documented crosstalk of CAR and connexins in ventricle is comparable to the me-




in conduction could explain both the AV-block and. It is important to note that different 
connexins are expressed in the conduction system and the myocardium. Furthermore, the 
preliminary expression profiling analysis indicated that the regulation of connexin expres-
sion in response to the loss of CAR differs between atrium and ventricle. Thus, altered 
communication of connexins can differentially affect the conduction system (AV-block 
and sick sinus syndrome) and the ventricle where the defect is compensated with no indi-
cation for electrical abnormalities but increased coupling. 
Towards understanding the molecular basis of the isolated AV-block, one would envision 
a mechanism where loss of CAR results in an altered protein composition of the tight 
junction, as documented by expression and immunofluorescence analysis (Fig. 11B and 
20). While the tight junction as a whole is not affected with normal ultrastructure and 
proper sublocalization of N-cadherin, connexins specifically respond to the loss of CAR 
with redistribution away from the intercalated disc and reduced protein levels can be ob-
served. This redistribution and reduction of connexins can potentially be due to a combi-
nation of reduced expression and degradation of mislocalized protein. The presence of 
CAR protein might have the function of stabilizing connexins at the intercalated discs. 
The AV-node shows less compartmentalization and a more homogenous distribution of 
CAR along the plasma membrane (Lisewski et al., 2008). This would explain the isolated 
effect on the AV-node where no predetermined structure such as the intercalated disc 
would facilitate proper electrical conduction.  
Multiple diseases have been associated with the tight junction, ranging from deafness and 
cancer to allergies and infections (Cereijido et al., 2007). This study describes a novel role 
for the tight junction in arrhythmia. Not only does this have implications for CAR as a 
potential diagnostic marker for familial cases of AV block, but it might also help explain 
how virus proteins or autoantibodies that interact with tight junction proteins such as 




cells is an important mechanism to disrupt CAR-CAR interaction at the tight junction and 
facilitate virus passing epithelial barriers (Walters et al., 2002). In the heart, this virus 
induced disruption of CAR-dimers would be expected to produce the same effect as the 
loss of CAR and thus ultimately lead to uncoupling and electrical conduction defects, 
which can accompany viral myocarditis (Kishimoto et al., 1984). Autoantibodies in 
rheumatic women have been shown to cause AV block by dysregulating Ca2+ homeostasis 
in cardiomyocytes (Salomonsson et al., 2005). A similar mechanism could result from 
autoantibodies that interfere with tight junction proteins.  
5.4 CAR expression levels determine the severity of the phenotype 
Germline deletion of CAR caused embryonic lethality with cardiac defect, but haploinsuf-
ficiency did now show any abnormalities. One can conclude that CAR is critical to the 
early stage of development when CAR appeared highly expressed, but a certain amount 
of CAR expression is sufficient to maintain normal physiological function during em-
bryonic development.  
The animals are less susceptible to loss of CAR after birth and in adulthood, cardiac spe-
cific deletion in adulthood did not affect the survival rate. Those animals developed a 
strong phenotype of AV-nodal block. The degree of AV-nodal block is dependent on the 
progression of induction, indicating that the atrial-ventricular conduction is regulated by 
the expression level of CAR. When CVB3 infected CAR deficient animals, cardiomyo-
cytes showed 100% resistance to the virus infection, while there was still <10% CAR 
expression. More CAR expression preserved, more side effects due to loss of CAR will 
be prevented. To minimize the side effects, it is necessary to investigate that to what ex-
tent, CVB3 entry can efficiently be blocked.  
Moreover, not only loss of CAR can protect hearts from virus entry and subsequent pa-




cardiac hypertrophy from volume overload stimulation. The result indicated that with less 
CAR expression, the heart could be protected from hypertrophy or at least, the progress of 
hypertrophy is delayed. CAR heterozygous animals have less receptor available, they 
have a potential to uptake less virus and alleviate the severity of the pathological changes 
after virus application.  
5.5 Conclusions 
Constitutive deletion of coxsackievirus and adenovirus receptor (CAR) is embryonic le-
thal at midgestation (E11.5) with impaired cardiac development and myofibril disorgani-
zation. Apolipoproteins were accumulated in the knockout heart, indicating CAR is in-
volved in lipid uptake. Connexin expression was decreased in the knockout, suggesting an 
abnormal cell-cell communication secondary to the loss of CAR. Those results indicated 
that CAR is a multi-functional protein that is essential for embryonic development. 
So far, various therapeutic approaches to combat CVB3 infection have been proposed. 
CAR-transgenic erythrocytes were used to redirect and capture virus particles (Asher et 
al., 2005a) or soluble CAR has been applied to compete with the cell surface receptor 
(Yanagawa et al., 2004; Lim et al., 2006; Dorner et al., 2006). While the former has led to 
reduced lethality, the latter has worked sufficiently in tissue culture (Goodfellow et al., 
2005) but produced inconsistent results in vivo either ameliorating or aggravating the dis-
ease process in mice (Dorner et al., 2006; Yanagawa et al., 2004; Lim et al., 2006). Based 
on the findings in this study one could speculate that CAR indeed provides a suitable tar-
get for the prevention and possible treatment of viral myocarditis. 
The potential unwanted effects that might result from the loss of CAR in the adult heart 
were addressed in the inducible CAR KO animals, which developed AV nodal block. The 




pression and localization of connexins that affect the communication between CAR 





6 Outlook  
Analyzing CAR deficient embryos helps to understand its role in embryonic development 
and physiological functions. So far, published data suggested that CAR is important for 
embryonic development and tissue homeostasis (Dorner et al., 2005; Asher et al., 2005b; 
Chen et al., 2006; Raschperger et al., 2006; Lim et al., 2008; Lisewski et al., 2008). This 
work provided the molecular basis underlying the embryonic lethality. However, data 
obtained in this study did not explain sufficiently if the phenotype is mediated by loss of 
the homophilic interaction of CAR between cells or via its role in endocytosis and signal 
transduction. Thus, it is necessary to distinguish the various cell type specific functions of 
CAR and the signaling pathways involved in embryonic development. To investigate the 
role of CAR in myofilament assembly, we have generated a GFP-tagged titin to label the 
sarcomere. This strain can be used to follow differentiation and fusion of cardiomyocytes 
and the transition of the myofilament between cells comparing CAR deficient and control 
animals. 
While the homozygous knockout displays a strong embryonic and distinct adult pheno-
type, we have so far not investigated a potential phenotype in heterozygous deficient ani-
mals in detail. One possibility would be the use of challenging conditions such as pres-
sure and volume overload or adrenergic stimulation. CAR haploinsufficient animals 
appeared phenotypically normal. After volume-overload, the animals only showed a slight 
tendency of reduced hypertrophy that could be increased with a stronger stimulus – pos-
sibly the combination of pressure overload and adrenergic stimulation. The heterozygous 
animals could also be used to investigate a potentially beneficial effect with less receptor 





We showed that CAR is necessary but not sufficient for CVB3 entry, and that loss of 
CAR can protect the heart from viral myocarditis with the potential for side effects that 
include AV-nodal block. Additional studies are needed to establish a save level for CAR 
to prevent pathology and reduce unwanted side effects. 
Since tamoxifen aggravates CVB3 induced myocarditis, it would be desirable to obtain a 
cardiac inducible Cre that uses a different agent to activate recombination, possibly using 
tetracycline-inducible expression of the recombinase. This model would facilitate the in-
vestigation of CAR’s therapeutic potential in the infected heart compared to the preven-
tion weeks before exposure to the virus. 
At this time, there is no genetic defect of CAR associated with human disease, but the 
findings here would suggest tight junction proteins as potential disease genes in genetic 
forms of isolated AV block. It might be possible to identify patients with reduced CAR 
levels (heterozygotes) in a cohort with inherited AV-block of unknown cause or patients 
with reduced susceptibility to viral myocarditis. 
Finally, the role of CAR in arrhythmogenesis has implications for CVB3 infection and 
patients with heart disease resulting from antibodies against proteins of the tight junction, 
which may lead to better screening methods to identify persons at risk of potentially fatal 
arrhythmia and possibly to novel therapies. 
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Tables of regulated genes in microarray: 
Table 12: List of upregulated genes in microarray (KO vs. WT) 
symbol  ko_wt_fc title  function  
Ambp  ++++ alpha 1 microglobulin/bikunin  transport, endopeptidase inhibitor activity  
Fgb ++++ fibrinogen, B beta polypeptide blood coagulation  
Apob  ++++ apolipoprotein B lipid metabolism  
Apoa1 ++++ apolipoprotein A-I lipid metabolism  
Lum ++++ lumican  unknown 
Afp +++ alpha fetoprotein ovulation, transport  
Slc2a2 +++ solute carrier family 2 (facilitated glucose transporter), member 2 carbohydrate transport  
Fgg  +++ fibrinogen, gamma polypeptide signal transduction  
Ttr  +++ transthyretin  thyroid hormone generation, transport  
Apom  +++ apolipoprotein M lipid transporter activity  
Postn  +++ periostin, osteoblast specific fac-tor 
extracellular matrix organization 
and biogenesis, cell adhesion  
Cubn  +++ cubilin (intrinsic factor-cobalamin receptor) 
lipid metabolism, receptor me-
diated endocytosis  
Cdh1 +++ cadherin 1 cell-cell adhesion, protein meta-bolism 
Tmprss2 +++ transmembrane protease, serine 2 serine-type endopeptidase activity  
Dkk2 ++ dickkopf homolog 2 (Xenopus laevis) 
Wnt receptor signaling pathway, 
development  
Paip1 ++ polyadenylate binding protein-interacting protein 1 
regulation of protein biosynthesis 
and translation  
Lasp1 ++ LIM and SH3 protein 1 ion transport, protein binding  
Smoc2 ++ SPARC related modular calcium binding 2 calcium ion binding  
Apoc2 ++ apolipoprotein C-II lipid metabolism  
Aldh1a7 + aldehyde dehydrogenase family 1, subfamily A7 metabolism  










Table 13: List of downregulated genes in microarray (KO vs. WT) 
symbol  ko_wt_fc title  function  
Cxadr ----- coxsackievirus and adenovirus receptor 
heart development, protein 
binding 
Fos  ---- FBJ osteosarcoma oncogene   regulation of transcription, DNA-dependent  
Egr1  ---- early growth response 1  regulation of transcription, DNA-dependent  
Ttyh3  ---- tweety homolog 3 (Drosophila)  chloride channel activity  
Rpo1-4  ---- RNA polymerase 1-4  protein binding, transcription  
Add3  ---- adducin 3 (gamma)  structural molecule activity, calmodulin binding  
Mrap  ---- melanocortin 2 receptor accessory protein  membrane protein  
Rgl1  --- Ral guanine nucleotide dissocia-tion stimulator,-like 1  
small GTPase mediated signal 
transduction  
Ly6a  --- lymphocyte antigen 6 complex, locus A  GPI anchor binding  
Abcb10  --- ATP-binding cassette, sub-family B (MDR/TAP), member 10  Transport, ATPase activity  
Rbm38  --- RNA binding motif protein 38  nucleotide binding  
Eraf  --- erythroid associated factor  
protein folding, erythrocyte 
differentiation, hemoglobin 
metabolism  
Il6st  --- interleukin 6 signal transducer   regulation of Notch signaling pathway  
Bcl2 -- B-cell leukemia/lymphoma 2 anti-apoptosis 
Amph  -- amphiphysin   learning, synaptic vesicle en-docytosis  
Tbc1d4  -- TBC1 domain family, member 4  intracellular signaling cascade  
Tmem153  -- transmembrane protein 153  unknown 
Kcnn4  - 
potassium intermediate/small 
conductance calcium-activated 
channel, subfamily N, member 4  
 positive regulation of protein 
secretion  
Slc4a1  - solute carrier family 4, member 1  anion exchanger 
Gja1 
(Cx43) - 
gap junction membrane channel 
protein alpha 1 Gap junction, cell-cell signaling 





Table of comparison of all available CAR knockout animal models 








































Exon Exon 2 Exon 11 Exon 2 Exon 2 Exon 2 Exon 2 Exon 2 Exon 1 Exon 1 Exon 1 
Constitutive + + +2   +3    + 




cre   
Inducible         MCM MCM 






















Ventr. Wall < > > > >= = = n.d. = > 
Apoptosis + - n.d. n.d. n.d. - - n.d. n.d. n.d. 
Fibrosis n.d. n.d. n.d. n.d. n.d. n.d. + - - - 
AV-block n.d. n.d. n.d. n.d. n.d. + + n.d. + + 
Sinus node n.d. n.d. n.d. n.d. n.d. n.d. n.d. n.d. + - 
Car-Function           
Cell Contacts n.d. - + n.d. n.d. n.d. + n.d. + + 
Myofilament n.d. + + n.d. n.d. n.d. - n.d. - + 
Compartment n.d. - n.d. n.d. n.d. n.d. n.d. + + + 
Remodeling + - n.d. n.d. n.d. n.d. + n.d. n.d. n.d. 
































KO knockout, w week, E embryonic day, n.d. not described; < decreased; > increased; >= 
slightly increased; = unchanged; + yes; - no 
1 from ATG 
2 converted with Protamine-Cre (PRMcre) 
3 -gal knock-in 






2-D electrophoresis two-dimensional gel electrophoresis 
ANP atrial natriuretic peptide 
AV atrioventricular 
AVB AV conduction block 
B.W. body weight 
BDM 2, 3- butanedione monoxime 
ß-ME ß-mercaptoethanol 
BNP brain natriuretic peptide 
bp base pair 
BSA bovine serum albumin 
CAR Coxsackievirus-Adenovirus-Receptor 
cDNA complementary DNA 
CHAPS 3-[(3-Cholamidopropyl)-dimethylammonio]-1-propanesulfonate 
CIP calf intestinal alkaline phosphatase 
Cre causes recombination 
C-terminus carboxy terminus 
CVB3 coxsackievirus B3 
Cx connexin 
DAF decay-accelerating factor 
DEPC diethylpyrocarbonate 
DIG digoxigenin 
DMEM Dulbecco's modified Eagle Medium 
DNA deoxyribonucleic acid 
DNase deoxyribonuclease 
dNTP 2’-deoxy nucleoside-5’-triphosphate 
dP/dtmax the maximum rate of ventricular pressure increase 
dP/dtmin the minimum rate of ventricular pressure drop 
dpc dias post coitus 
DTT dithiothreitol 
ECG electrocardiogram 
ECL enhanced chemiluminescence 
EDTA ethylene-diamine-tetraacetic acid 
EF ejection fraction 
ES Embryonic stemcell 
FA formamide 
FBS fetal bovine serum 
FCS fetal calf serum 
H&E hematoxylin and eosin 
H2O2 hydrogen peroxide 
HRP horse radish peroxidase 
HV his-ventricle 
IFN-α interferon alpha 
IFN-β interferon beta 
IFN-γ interferon gamma 




kDa kilo Dalton 
KO knockout 
LCK lymphocyte protein tyrosine kinase 





NBT nitroblue-tetrazolium salt 
NEAA None-essential amino acids 
NP-40 Nonidet P-40 Substitute, Nonylphenyl-polyethylene glycol 
N-terminus amino terminus 
o/n overnight 
OD optical density 
PAGE polyacrylamide gel electrophoresis 
PBS phosphate buffered saline 
PCR polymerase chain reaction 
PFA paraformaldehyde 
pfu plaque-forming unit 
pI isoelectric point 
pIpC polyinosinic-polycytidylic ribonucleic acid 
Pmax maximum P-wave duration 
Pmin minimum P-wave duration 
PMSF phenylmethanesulfonyl fluoride 
P/S Penicillin/Streptomycin 
RNA ribonucleic acid 
RNase ribonuclease 
rpm rotations per minute 




Taq thermus aquaticus 
TBS tris buffered saline 
TE tris-EDTA-buffer 
TEMED N, N, N`, N´-Tetramethylethylendiamin 
TNFα Tumor necrosis factor-alpha 
Tris tris(hydroxymethyl)-aminomethane 
Triton X-100 polyethylene glycol octylphenol ether 
U unit 
UTP uridine triphosphate 
V volt 
VP1 major capsid protein 
WT wildtype 
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